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T-cell acute lymphoblastic leukemia (T-ALL) is a rare but aggressive T-cell malignancy that is a 
subset of acute lymphoblastic leukemia. T-ALL comprises approximately 15% of childhood and 
25% of adult cases. It is most common in children but these patients can relapse. While the 5-
year survival rate in children (80%) has improved significantly due to advances in chemotherapy, 
primary resistant and relapsed cases are still dismal which argue for more treatment options. 
Many current therapies target T-ALL through DNA damage or synthesis often causing toxicity 
in healthy cells. Our lab has identified and developed novel agents that induce apoptosis in T-
ALL cells, which are selective inhibitors of the enzyme geranylgeranyl diphosphate synthase 
(GGDPS). GGDPS is an enzyme in the isoprenoid biosynthesis pathway that produces 
geranylgeranyl diphosphate (GGPP) whose lipid moiety is post-translationally attached to small 
GTPases allowing GTPases to be membrane-associated and exert their function at the 
membrane. Here, I investigate the mechanism of apoptosis induced by GGDPS inhibitors and 
compare GGDPS inhibitors with current therapies. GGDPS inhibition is more potent than 
zoledronate, an isoprenoid biosynthesis pathway inhibitor used clinically against bone 
malignancies. Interestingly, GGDPS inhibitors are minimally toxic towards healthy PBMCs 
compared to zoledronate. GGDPS inhibitors and zoledronate also alter membrane localization of 
different small GTPases. I establish the role of ERK activation and caspase cleavage in GGDPS 
   
 
inhibitor-induced apoptosis, and importantly, I also determine that GGDPS inhibition-induced 
apoptosis is also mediated by Notch1, ATM and c-abl. C-abl is at the crux of the DNA damage 
response pathway as it is both involved in DNA damage repair and DNA damage-induced 
apoptosis. Interestingly, T-ALL cells show high levels of DNA damage yet do not undergo 
apoptosis. I predict that GGDPS inhibition circumvents this evasion of apoptosis through 
depleting levels of active Notch1, and allowing for the activation of ATM, and cleaving of c-abl. 
Therefore, I hypothesize that GGDPS inhibition targets cells with high levels of DNA damage. 
Overall, I explore how T-ALL cells use Notch1, ATM, and c-abl to avoid DNA damage-induced 
apoptosis and how inhibition of GGDPS overcomes this regulation.  
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CHAPTER 1. MOLECULAR MECHANISMS LINKING 
GERANYLGERANYL DIPHOSHATE SYNTHASE TO CELL 
SURVIVAL AND PROLIFERATION. 
 
Abstract 
Geranylgeranyl diphosphate is a twenty-carbon isoprenoid phospholipid whose lipid 
moiety can be post-translationally incorporated into proteins to promote membrane association. 
The process of geranylgeranylation has been implicated in anti-proliferative effects of clinical 
agents that inhibit enzymes of the mevalonate pathway (i.e. statins and nitrogenous 
bisphosphonates) as well as experimental agents that deplete geranylgeranyl diphosphate. 
Inhibitors of geranylgeranyl diphosphate synthase are an attractive way to block 
geranylgeranylation because they utilize beneficial chemical features of the bisphosphonate 
substructure and take advantage of a unique position of the enzyme within the biosynthetic 
pathway. Here, we describe recent advances in geranylgeranyl diphosphate synthase expression 
and inhibitor development with a particular focus on the molecular mechanisms that link 
geranylgeranyl diphosphate to cell proliferation via geranylgeranylated small GTPases. This 
chapter was adapted from a previous publication (Agabiti et al., 2016). 
Introduction 
Post-translational attachment of a lipid group to a protein is commonly used by cells to 
promote association of the protein with a biological membrane (Palsuledesai and Distefano, 
2015). The enzymes of protein prenylation specifically utilize intermediates of cellular 
isoprenoid biosynthesis as substrates to modify one or two cysteine residues near the C-terminus 
of the protein. Prenylation may refer to incorporation of the fifteen-carbon molecule farnesyl 
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diphosphate (farnesylation) or the twenty-carbon geranylgeranyl diphosphate 
(geranylgeranylation) onto a protein. The specific modification depends upon the amino acid 
sequence found at the C-terminus of that particular protein. Both types of prenylation are 
directed by the CaaX motif- composed of a cysteine followed by three additional amino acid 
residues (Reid et al., 2004), though in some Rab proteins geranylgeranylation can occur at two 
cysteine residues with other consensus sequences.  
Because many small GTPases of the Ras superfamily are prenylated, inhibition of protein 
prenylation has been viewed as a potential therapeutic target for diseases in which GTPases 
contribute to the pathogenesis (Berndt et al., 2011, Hottman and Li, 2014, Cox et al., 2015). The 
majority of these studies have examined disrupting farnesylation of Ras family members H-, N- 
and K-Ras, which are known oncogenes.  Other small GTPases, such as RhoA, also have been 
reported to play roles in survival and proliferation of malignant cells (Qiu et al., 1995, Ghosh et 
al., 1999, Allal et al., 2000, Yoshida et al., 2009) and altering the membrane localization of 
RhoA can reduce proliferation (Adnane et al., 1998, Li et al., 2002, Denoyelle et al., 2003, 
Fromigue et al., 2006, Tang et al., 2006, Zhu et al., 2013). While these and other studies have 
clearly shown that disruption of prenylation can reduce proliferation of malignant cells, the 
clinical potential of prenylation inhibitors for treatment of disease is often limited because: 1) 
prenylated proteins can be critical to the function of healthy normal cells, 2) direct inhibition of 
prenylation enzymes in cells can be overcome by activation of alternative prenylation pathways, 
and 3) prenylation and the membrane association that it promotes is not always required for 
protein activity. Although much effort has been devoted to pre-clinical development of prenyl 
transferase inhibitors, these compounds have not yet gained clinical relevance. 
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In contrast, bisphosphonate-based inhibitors of cellular isoprenoid biosynthesis and 
protein prenylation have achieved clinical success (Ebetino et al., 2011, Clezardin et al., 2011). 
Although they can be associated with mechanism-based side effects such as osteonecrosis in a 
small percentage of patients, these drugs greatly reduce the risk of fractures resulting from 
osteoporosis (Russell et al., 2008). Additionally, they are now frequently used for treatment of 
cancer-related skeletal complications (Ibrahim et al., 2003) that arise from both solid tumor 
metastases (Gnant, 2012) and hematological diseases such as myeloma (Terpos et al., 2014) 
where they prevent growth of the malignant cells in the bone environment. The nitrogen-
containing bisphosphonates appear to function primarily by blocking isoprenoid biosynthesis 
(Amin et al., 1992, Shipman et al., 1998) leading to protein prenylation (van Beek et al., 1999b, 
Bergstrom et al., 2000). In osteoclasts, this results in loss of bone resorption but in malignant 
cells this reduces proliferation. Nitrogenous bisphosphonates overcome some of the limitations 
of prenyltransferase inhibitors in this regard because they exhibit reduced effects on healthy cells 
through enriched distribution to the bone compartment and they prevent alternative prenylation 
through inhibiting an upstream enzyme, farnesyl diphosphate synthase (FDPS).  
While FDPS is the molecular target of the clinical bisphosphonates, the molecular 
mechanism of action is often linked to downstream depletion of geranylgeranyl diphosphate. 
Therefore, bisphosphonate-based compounds that target other enzymes of isoprenoid 
biosynthesis (Wiemer et al., 2009) leading to geranylgeranyl diphosphate production may be 
viable therapies for GTPase-dependent disorders affecting the bone environment (Wiemer et al., 
2011), and could be useful tools for understanding the biological consequences of geranylgeranyl 
diphosphate depletion in cells. This mini-review examines recent developments in our 
understanding of the relationship between geranylgeranyl diphosphate synthase (GGDPS) and 
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cell survival and proliferation, which are affected by geranylgeranylated proteins in the 
membrane domain. 
Expression and regulation of GGDPS 
GGDPS is a ubiquitously-expressed 35 kDa enzyme found within the isoprenoid 
biosynthetic pathway (also known as the mevalonate pathway) (Wiemer et al., 2011) (Figure 1). 
In human cells, GGDPS has been reported to form a large multimeric complex, which was 
initially characterized as an octomer (tetramer of dimers) (Kuzuguchi et al., 1999) but 
subsequently reported as a hexamer (trimer of dimers) (Kavanagh et al., 2006a). Further 
biochemical studies appear to support the octomer model (Miyagi et al., 2007). Like FDPS, 
GGDPS is a prenyl synthase enzyme. Together, these enzymes produce the farnesyl diphosphate 
and geranylgeranyl diphosphate, respectively. GGDPS catalyzes the condensation of farnesyl 
diphosphate and isopentenyl diphosphate to geranylgeranyl diphosphate via an ionization-
condensation-elimination mechanism (Poulter et al., 1978). Thus, depletion of either substrate 
may decrease GGDPS activity. GGDPS also has an additional binding site where geranylgeranyl 
diphosphate may bind and inhibit the enzymatic activity (Kavanagh et al., 2006a, Guo et al., 
2007). Farnesyl diphosphate and geranylgeranyl diphosphate, can subsequently be utilized as 
substrates by the prenyl transferase enzymes (farnesyl transferase and geranylgeranyl 
transferases I and II) as described above. Post-translational incorporation of the prenyl moiety 
increases membrane association of modified proteins, which is generally but not always required 
for normal activation and signaling. 
Many isoprenoid biosynthetic pathway enzymes are regulated at the transcriptional level 
to control isoprenoid production (Figure 2). The classical model of this effect is observed when 
statin drugs are used to inhibit HMG-CoA reductase leading to the depletion of intracellular 
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cholesterol (Brown and Goldstein, 1980). Cholesterol depletion triggers a restorative feedback 
response mediated by sterol regulatory element binding transcription factors, which upon 
translocation into the nucleus induce transcription of HMG-CoA reductase (Hua et al., 1993, 
Brown and Goldstein, 1997, Brown and Goldstein, 2009) (Figure 2A). It is unclear whether 
GGDPS expression is strongly dependent on sterol regulatory elements, though evidence 
suggests that its regulation by these factors is not as dramatic as the upstream enzymes such as 
HMG-CoA reductase. Nonetheless, inhibition of GGDPS leads to diversion of farnesyl 
diphosphate into sterol synthesis, which has an effect that is opposite to that of statins and 
nitrogenous bisphosphonates-decreased transcription of HMG-CoA reductase (Wiemer et al., 
2011). Thus, in contrast to HMG-CoA reductase inhibition, cells appear to have a reduced ability 
to overcome the effects of GGDPS inhibition at the transcriptional level. 
Sterol regulatory elements are not the only potential transcriptional regulators of GGDPS 
and other isoprenoid pathway enzymes. Activation of the extracellular signal-regulated kinase 
(ERK) pathway can activate the zinc-dependent transcription factor early growth response gene 1 
(EGR1) to regulate expression of HMG-CoA reductase and other sterol pathway enzymes 
(Gokey et al., 2011) (Figure 2B). In contrast to transcription controlled by sterol regulatory 
elements, constitutively active EGR1 may also regulate GGDPS expression by upregulating 
transcription of the GGDPS gene, which forms a positive feedback loop (Shen et al., 2011). This 
pathway can be activated by insulin (Yu et al., 2011) and toxins such as cigarette smoke extract 
(Shen et al., 2011), which stimulate the ERK pathway and promote accumulation of EGR1 (Tao 
et al., 2013). But the relationship between EGR1 and GGDPS needs further investigation as 
inhibition of EGR1 transcription had no effect on GGDPS mRNA and protein levels in MCF-7 




Upregulation and/or dysregulation of the isoprenoid biosynthetic pathway enzymes 
including GGDPS has been indicated in oncogenic progression (Pandyra et al., 2015), 
demonstrating an important link between isoprenoids and cell survival and proliferation. For 
example, dysregulation of the mevalonate pathway by ectopic expression of HMG-CoA 
reductase promotes transformation of liver cells (Clendening et al., 2010). Additionally, mutant 
p53 can contribute to malignant cell morphology in mammary tissue in a way that is dependent 
upon the mevalonate pathway (Freed-Pastor et al., 2012). In cells depleted of mutant p53, the 
addition of mevalonate pathway metabolites could compensate for the loss of mutant p53 by 
restoring the invasive morphology. GGDPS itself is associated with development of liver cancer. 
In tissue from hepatocellular carcinoma patients, GGDPS mRNA expression was elevated in 
85.29% of tumor tissue compared to surrounding cells (Yu et al., 2014). Correspondingly, they 
found that GGDPS protein expression was increased in tumor tissue compared to adjacent tissue 
in 11 of 15 patients. 
While GGDPS expression is ubiquitous and its enzymatic product is often required for 
proliferation (Benford et al., 1999, van de Donk et al., 2003, Inoue et al., 2005, Brinkkoetter et 
al., 2006, Baulch-Brown et al., 2007, Sonnemann et al., 2007, Wiemer et al., 2007, Yanae et al., 
2011, Tsubaki et al., 2013, Zafar et al., 2014), there is only limited evidence, as described in the 
preceding paragraph, to suggest a higher degree of GGDPS mutation in malignant cells relative 
to normal cells. Therefore, GGDPS inhibitors could be best classified as anti-metabolites 
targeting membrane domain proteins (Bennis et al., 1993, Mo and Elson, 2004). Even without 
malignant versus normal selectivity, therapeutic specificity could still be obtained by tissue-
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specific distribution such as that which directs bisphosphonates to localize to the bone 
environment due to the affinity of the substructure for calcium.  
Geranylgeranyl diphosphate synthase inhibitors 
Bisphosphonate-based drugs, such as alendronate (Figure 3, compound 1), have been 
used therapeutically in humans for over half a century (Ebetino et al., 2011). In fact, the 
nitrogenous bisphosphonates that inhibit FDPS gained therapeutic use prior to determination of 
their molecular mechanism of action. These agents were selected in part because of the 
usefulness of the bisphosphonate substructure for binding calcium ions. It was later revealed that 
the nitrogenous bisphosphonates act as potent inhibitors of FDPS. However, the cellular effects 
of bisphosphonates on osteoclast-mediated bone resorption are not due to depletion of the 
immediate enzymatic product, farnesyl diphosphate, but rather to depletion of the subsequent 
molecule in the pathway, geranylgeranyl diphosphate (van beek et al., 1999a). Around the same 
time, it was demonstrated that the bisphosphonate substructure is useful for targeting inhibitors 
such as compound 2 to squalene synthase (Ciosek et al., 1993). As bisphosphonates can be 
viewed as analogs of diphosphates, one could readily hypothesize that other enzymes that 
metabolize diphosphate, such as GGDPS, may also be targeted by bisphosphonate-based drugs. 
Initial studies on GGDPS demonstrated that lipophilic bisphosphonates such as 
compound 3 inhibit the enzyme, while the nitrogenous bisphosphonate drugs do not (Bergstrom 
et al., 2000, Szabo et al., 2002). Given this knowledge, it was hypothesized that bisphosphonates 
bearing isoprenoid substituents may also function as GGDPS inhibitors. We synthesized and 
characterized an initial library of bis-prenyl bisphosphonates (Shull et al., 2006) including 
digeranyl bisphosphonate (4), demonstrating potent inhibition of cellular geranylgeranylation 
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with no effect on cellular farnesylation. Subsequent studies revealed nanomolar inhibition of 
GGDPS with no inhibition of FDPS (Wiemer et al., 2007, Wiemer et al., 2008a). 
Lipophilic bisphosphonates bind up to three sites in the GGDPS enzyme (Guo et al., 
2007), including both the substrate binding pockets of isopentenyl diphosphate and farnesyl 
diphosphate, as well as a geranylgeranyl diphosphate product/inhibitory binding site. Further 
studies comparing bis-prenyl and mono-prenyl bisphosphonates showed potent GGDPS 
inhibition of both types of compounds (Wiemer et al., 2008a). Structural analysis demonstrated 
that branched bisphosphonates such as digeranyl bisphosphonate (DGBP) bind to the enzyme 
with the bisphosphonate in complex with two magnesium ions and the dual alkyl chains 
extending into the farnesyl diphosphate substrate and the geranylgeranyl diphosphate product 
binding sites (Chen et al., 2008). 
Shorter-chain mono-alkyl nitrogenous bisphosphonates (e.g. compound 5) allow for dual 
inhibition of FDPS and GGDPS (Zhang et al., 2009). Compound 5 demonstrated good anti-
tumor activity in a mouse model of breast cancer. Additionally, the authors argued that these 
GGDPS inhibitors may be effective anti-malarial compounds, due to their two-fold effect (Zhang 
et al., 2013): 1) inhibition of the parasite GGDPS enzyme causes direct inhibition of parasite 
growth, and 2) inhibition of human FDPS causes  activation of a human immune response 
through indirect activation of gamma delta T cells. Both mono-aromatic non-nitrogenous 
bisphosphonates (Barney et al., 2010) and triazole-based compounds such as compound 6 appear 
to retain specificity for inhibition of GGDPS over FDPS, in contrast to mono-alkyl nitrogenous 
bisphosphonates which appear to inhibit both FDPS and GGDPS (Zhou et al., 2014). In fact, a 
recently identified triazole-based compound (7) is the most potent GGDPS inhibitor described to 
date (Wills et al., 2015). 
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While most reports have examined modifications to the bisphosphonate substructure, 
non-bisphosphonate inhibitors of GGDPS have also been recently described (e.g. compound 8) 
(Chen et al., 2013). Although these compounds are significantly less potent inhibitors of 
GGDPS, they retain specificity over FDPS. Lack of the bisphosphonate would be expected to 
increase peripheral distribution, which could increase the relevance for treatment of non-bone 
disorders that are dependent upon geranylgeranylation. However, this strategy may also result in 
increased toxicity towards healthy peripheral tissues. Taken together, a diverse group of 
bisphosphonate and non-bisphosphonate based GGDPS inhibitors has been developed, yielding a 
variety of options with respect to target specificity and cellular availability that could determine 
the consequences of geranylgeranyl diphosphate depletion. 
GGDPS inhibitors as anti-proliferative agents targeting small GTPases 
Several groups have examined the anti-proliferative activity of compounds that inhibit 
the enzymes of the isoprenoid pathway. The major premise is that protein prenylation is vital to 
cell growth and survival and that blocking prenylation through isoprenoid depletion would 
negatively impact cell health. While it is straightforward to broadly determine whether 
prenylation is required for proliferation in a given system, it is more difficult to determine which 
specific prenylated proteins mediate the effect. This problem is especially difficult with respect 
to geranylgeranylation, because approximately two thirds of the over 150 prenylated proteins are 
predicted to be geranylgeranylated rather than farnesylated (Reid et al., 2004, Maurer-Stroh et 
al., 2007). Many of these proteins are small GTPases of the Ras superfamily, which is typically 
divided into five families based on sequence and functional homology (Ras, Rho, Rab, Ran and 
Arf) (Wennerberg et al., 2005). While the Ras family GTPases are known to regulate 
proliferation, these proteins are predominately farnesylated and usually geranylgeranylated only 
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when their farnesylation is blocked. In contrast, the Rho and Rab GTPases, while predominately 
geranylgeranylated, are traditionally thought to function mainly in cytoskeletal reorganization 
and vesicle trafficking, respectively. Their roles in proliferation are less clear. Here, we examine 
the connection between geranylgeranylated small GTPases and the anti-proliferation phenotype 
caused by geranylgeranyl diphosphate depletion in order to determine whether GGDPS 
inhibitors would reduce proliferation by affecting a particular GTPase or GTPase family. 
In some cases, the anti-proliferative effect caused by isoprenoid depletion using HMG-
CoA reductase inhibitors (statin drugs) or FDPS inhibitors (bisphosphonate drugs) is dependent 
upon reduced prenylation of oncogenic small GTPases. The primary rationale for developing 
direct prenylation inhibitors (e.g. farnesyl transferase inhibitors) as anti-cancer agents stemmed 
from the finding that H- N- and K-Ras, which are among the most commonly mutated 
oncogenes, are primarily farnesylated (Cox et al., 2015). Isoprenoid biosynthesis inhibitors or 
farnesyl transferase inhibitors can block Ras prenylation, in turn reducing Ras signaling and 
preventing cellular growth. For example, in some human leukemia cells the HMG-CoA 
reductase inhibitor lovastatin potentiates the cell toxicity of a checkpoint inhibitor, which is 
abrogated by ectopic expression of constitutively active Ras leading to elevated downstream 
ERK signaling (Dai et al., 2007). 
At times some Ras isoforms can be geranylgeranylated when their farnesylation is 
blocked (Whyte et al., 1997), suggesting that farnesyl transferase is not an ideal target for 
disrupting Ras prenylation. Some groups have proposed combining farnesyl transferase 
inhibitors with geranylgeranyl transferase inhibitors to achieve complete Ras blockade (Lobell et 
al., 2001). However, another potential route to overcome this limitation is to utilize a prenyl 
synthase inhibitor which acts upstream to deplete both farnesyl and geranylgeranyl diphosphate, 
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and block both routes of prenylation. For example, exposure to a lipophilic bisphosphonate 
decreases the plasma membrane levels of K-Ras and H-Ras and leads to caspase dependent 
apoptosis (Xia et al., 2014). Targeting only farnesyl transferase lacked clinical efficacy, therefore 
targeting multiple isoprenoid enzymes may be more advantageous (Cox et al., 2015), provided 
that unwanted toxicity to healthy cells can be avoided through other means such as tumor-
specific delivery.  
Although Ras is mutated in a number of cancers like pancreatic and lung 
adenocarcinomas (McCormick, 2015, Padavano et al., 2015), the majority of prenylated proteins 
are not mutated in cancer (Alan and Lundquist, 2013). Notable exceptions are that dominant 
negative RhoA can be found in angioimmunoblastic T-cell lymphoma and mutated RhoH can be 
found in non-Hodgkin lymphoma and multiple myeloma (Preudhomme et al., 2000, Nagata et 
al., 2016). However, even these non-mutated prenylated proteins can still be targets for cancer 
therapy because of their role in cell proliferation. Targeting prenylation requires that both the 
protein and its prenylated state are important in proliferation. For instance, Rac, which is a 
substrate of geranylgeranyl transferase I, has been shown to be involved in proliferation and 
decreasing prenylation decreases proliferation (Baba et al., 2008). Despite these advantages, it is 
challenging to identify the specific protein involved in the pathway because many GTPases share 
effector and regulatory proteins and the exogenous expression of one GTPase may influence the 
activity of other GTPases. 
Taking those caveats into account, most studies have implicated geranylgeranylation of 
Rho family proteins, specifically RhoA, as a mediator of the anti-proliferative effects of 
geranylgeranyl diphosphate depletion. For example, depletion of geranylgeranyl diphosphate 
interrupts the transition from G1 to S phase in thyroid cells by preventing a decrease in p27 
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expression (Hirai et al., 1997). The phenotype is rescued by co-incubation with exogenous 
geranylgeranyl diphosphate. However, in the presence of botulinum C3 exoenzyme (which 
specifically inhibits Rho proteins), geranylgeranyl diphosphate is unable to rescue the phenotype. 
Thus, the authors concluded that geranylgeranylation of Rho is required for proliferation of these 
cells. 
In vascular smooth muscle cells, statins induce an apoptotic effect, which is rescued by 
co-incubation with either farnesyl or geranylgeranyl diphosphate, indicating a role for 
geranylgeranylation in the apoptotic mechanism. Overexpression of constitutively active RhoA 
(L63) reduces the effect of the statin on apoptotic DNA laddering (Blanco-Colio et al., 2002). In 
endothelial cells, statins potentiate apoptosis induced by tumor necrosis factor-α. This effect is 
due to reduced RhoA geranylgeranylation, because the phenotype can be mimicked by 
expression of a dominant negative RhoA construct (N19). More importantly, the effect of the 
statin can be rescued by expression of constitutively active RhoA (L63) (Tang et al., 2006). In 
osteosarcoma cells, statin treatment induces caspase-dependent apoptosis. Here, the authors 
demonstrated that atorvastatin increases caspase activity, which is rescued by constitutively 
active RhoA (V14) but not wild-type RhoA (Fromigue et al., 2006). In a well-designed study, 
Allal et al. generated plasmids coding for farnesylated-RhoA and farnesylated-RhoB in which 
the CAAX domain is mutated to a farnesylation sequence (CVLS) as opposed to the normal 
geranylgeranylation sequence (CVLV). They found that farnesylated-RhoB and not farnesylated 
RhoA evades G0/G1 cell cycle arrest induced by geranylgeranyl transferase inhibition (Allal et 
al., 2002). Together, these studies provide mechanistic evidence for a requirement of not only 
Rho but also of Rho geranylgeranylation for cell proliferation and survival. 
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While disruption of RhoA geranylgeranylation resulting in mislocalization has negative 
consequences on proliferation and survival, it is unclear in some cases whether disruption of 
geranylgeranylation inhibits or activates RhoA signaling. For example, in HepG2 cells, a 
decrease in RhoA activity is implicated in mediating apoptosis via lipophilic statins (Maeda et 
al., 2010). These effects are rescued by addition of geranylgeranyl diphosphate. Similarly, in 
colorectal cancer cells, treatment with a statin induces apoptosis, which is rescued by exogenous 
geranylgeranyl diphosphate but not farnesyl diphosphate (Zhu et al., 2013). In contrast to the 
HepG2 cells, partial rescue of the statin-induced phenotype is observed not only with RhoA 
silencing, but also with Rac1 silencing, Rac1 inhibitors, and expression of dominant negative 
Rac1 (N17). This led the authors to suggest not only that both RhoA and Rac1 mediate the 
effects of statins in this system, but also that statins elevate (rather than reduce) Rho and Rac 
signaling activity, which leads to apoptosis. 
These results agree with a prior study that observed GTPase activation in macrophages 
that had been treated with nitrogenous bisphosphonates. In the macrophage system, increases are 
observed in RhoA, Rac1, and Cdc42 GTP binding in response to isoprenoid depletion. The 
authors propose that mislocalization of the improperly prenylated proteins may restrict their 
ability to interact with their regulatory partners. Furthermore, in this system Rac1 silencing was 
able to block the increase in p38 phosphorylation that was also observed (Dunford et al., 2006). 
The Ras family members RalA and RalB have also been implicated in the phenotypes 
caused by inhibition of geranylgeranylation (Falsetti et al., 2007). Here, the authors examined the 
mechanism of growth inhibition that was induced by geranylgeranyl transferase type I inhibitors 
in pancreatic cancer cells. Treatment with the geranylgeranyl transferase inhibitors causes 
anchorage-independent growth and induces apoptosis. These studies used RalA and RalB 
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constructs in which the CAAX prenylation signal had been altered to allow these naturally 
geranylgeranylated proteins to be modified instead by farnesylation. Interestingly, the 
farnesylated RalB construct rescued the apoptotic phenotype while expression of the farnesylated 
RalA construct rescued the anchorage-independent growth phenotype. 
Rap1 is another geranylgeranylated GTPase that may play a role in tumor malignancy. 
While mechanistic studies demonstrating functional significance of Rap1 prenylation to the anti-
proliferative phenotypes of isoprenoid biosynthesis inhibitors are lacking, the development of 
antibodies to the non-prenylated form of Rap1 have facilitated the in vitro study of 
geranylgeranylation by eliminating the need for preparing cytoplasmic and membrane fractions 
for Western blot analysis. Rap1 is routinely used as a biomarker for cellular geranylgeranylation, 
and is especially useful for in tissue studies in which tissue for analysis is limited, precluding 
analysis by subcellular fractionation. For example, Rap1 geranylgeranylation was detected to be 
impaired by GGDPS inhibitors at metastatic sites in the adrenal gland and mesenteric metastatic 
sites, while it was not altered in non-tumorous adrenal glands. Corresponding with the inhibition 
of Rap1 prenylation, mice treated with the GGDPS inhibitor also show reduced tumor burden 
(Reilly et al., 2015a). 
An important advantage of GGDPS inhibition is the ability to impair geranylgeranylation 
of proteins that are modified by both geranylgeranyl transferase type I, which I modifies Rho 
family proteins like Rho, Rac, cdc42 and type II, which modifies members of the Rab family 
(Stigter et al., 2012). These proteins have been traditionally associated with regulation of 
membrane trafficking, however there is recent evidence implicating Rab prenylation in the anti-
proliferative effect of isoprenoid depletion. For example, it has been reported that overexpression 
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of Rab27B can promote tumor growth (Hendrix et al., 2010). Mutants of Rab27B that are 
deficient in their prenylation lack this effect. 
The impact of Rab GTPases is also seen in inhibitor studies. Both zoledronate and a 
geranylgeranyl transferase inhibitor decrease the membrane to cytoplasmic ratios of RhoA, 
Cdc42 and Rab6. Most notably, the effects of zoledronate are similar to that of a geranylgeranyl 
transferase II inhibitor suggesting that the effects of zoledronate likely depend on the 
geranylgeranylation of Rab proteins including Rab6. Zoledronate ultimately induces apoptosis in 
some cells and S-phase cell cycle arrest in others. An inhibitor of geranylgeranyl transferase II 
also demonstrated a similar effect, and the authors suggested that zoledronate-mediated apoptosis 
was driven by loss of Rab geranylgeranylation (Okamoto et al., 2014). 
In addition to roles in cell proliferation regulation, Rab geranylgeranylation has been 
implicated in regulation of autophagy. Geranylgeranyl diphosphate depletion in response to 
GGDPS inhibition increases expression of LC3-II  (Wasko et al., 2011, Dykstra et al., 2015), 
indicative of autophagy (Tanida et al., 2008). Co-incubation with exogenous geranylgeranyl 
diphosphate prevented accumulation of LC3-II and impairment of Rab geranylgeranylation 
caused by isoprenoid depletion. Dykstra found that geranylgeranyl transferase I inhibitor (GGTI-
2133) is not able to induce LC3-II accumulation despite effective inhibition of 
geranylgeranylation (Dykstra et al., 2015). Moreover, knockdown of GGDPS induces autophagy 
and delays tumor growth in vivo (Jiang et al., 2014). 
Conclusion 
While many papers have shown that depletion of isoprenoids or small GTPases has a 
negative impact on proliferation and viability, fewer have investigated whether the anti-
proliferative effects of isoprenoid depletion can be rescued by molecular manipulation of a 
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prenylated small GTPase. The more successful approaches have been to rescue proliferation with 
either an alternatively prenylated construct or a constitutively active construct, or fail to rescue 
with exogenous isoprenoid plus a dominant negative construct or inhibitor. In some cases, 
GTPase mislocalization causes activation rather than inactivation, and the phenotype can be 
directly rescued with a GTPase inhibitor. The studies described herein show that although there 
are dozens of predicted geranylgeranylated proteins, the anti-proliferative mechanism of 
geranylgeranyl diphosphate depletion can at times rest on mislocalization of a single 
geranylgeranylated small GTPase. RhoA geranylgeranylation has been the most frequently 
described critical lynchpin, but the phenomenon varies by model system, with Rac, Ral, and even 
Rab geranylgeranylation mediating the anti-proliferative effects in some models. By extension, 
inhibitors of GGDPS or the geranylgeranyl transferases may be most relevant to indications that 
depend upon the function of RhoA or its related proteins. Future studies on the consequences of 
disrupting geranylgeranylation would be aided by molecular approaches that identify the specific 





Figure 1. Location of geranylgeranyl diphosphate synthase (GGDPS) within the 
human isoprenoid biosynthetic pathway.  
The first and rate-limiting step of human isoprenoid synthesis is the conversion of HMG-CoA to 
mevalonate by HMG-CoA reductase (HMGCR). This enzyme is the molecular target of the 
statin drugs. Several steps downstream, farnesyl diphosphate synthase (FDPS) catalyzes the 
production of farnesyl diphosphate (FPP) from dimethylallyl diphosphate DMAPP and two 
equivalents of isopentenyl diphosphate (IPP). This enzyme is the molecular target of the 
nitrogenous bisphosphonates. Farnesyl diphosphate is a key branch point of isoprenoid 
metabolism, giving rise to squalene in a reaction catalyzed by squalene synthase (SQS) and 




Figure 2. Key feedback mechanisms that control isoprenoid biosynthetic gene 
expression at the transcriptional level.  
A) Sterol regulatory element-binding proteins (SREBPs) regulate transcription of HMG-CoA 
reductase and other enzymes of isoprenoid biosynthesis in response to cellular sterol levels, 
which indirectly affects synthesis of geranylgeranyl diphosphate. B) Egr-1 regulates transcription 
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of isoprenoid biosynthesis in response to activation of the ERK pathway, which directly 





Figure 3. Structural evolution of GGDPS inhibitors.  
Small nitrogen-containing bisphosphonates are inhibitors of farnesyl diphosphate synthase 
(FDPS). Lipophilic bisphosphonates can inhibit the enzymes of farnesyl diphosphate 
metabolism, including GGDPS and squalene synthase. Branched bisalkyl bisphosphonates retain 





Figure 4. Geranylgeranylation of small GTPases including Rac, Rho, Rab, and 
Cdc42 promotes localization to the membrane domain, affecting proliferation.  
Geranylgeranyl transferase I catalyzes the addition of geranylgeranyl diphosphate to the C-
terminus of Rho, Rac, or Cdc42 while geranylgeranyl transferase II catalyzes the addition of one 
or two geranylgeranyl moieties to Rab GTPases. Rab GTPases are primarily involved in vesicle 
trafficking, though disruption of Rab geranylgeranylation can affect cell viability and 





CHAPTER 2: GERANYLGERANYL DIPHOSPHATE SYNTHASE 
INHIBITION INDUCES APOPTOSIS THAT IS DEPENDENT UPON 




Bisphosphonates are diphosphate analogs that inhibit the intermediate enzymes of the 
mevalonate pathway. Here, we compared the effects of a farnesyl diphosphate synthase (FDPS) 
inhibitor, zoledronate, and a geranylgeranyl diphosphate synthase (GGDPS) inhibitor, digeranyl 
bisphosphonate (DGBP), on lymphocytic leukemia cell proliferation and apoptosis. Both 
zoledronate and DGBP inhibited proliferation with DGBP doing so more potently. DGBP was 
markedly less toxic than zoledronate towards the viability of healthy human peripheral blood 
mononuclear cells. Addition of GGPP, but not farnesyl diphosphate (FPP), prevented the anti-
proliferative effects of DGBP. Both GGPP and FPP partially rescued the effects of zoledronate. 
Co-treatment with DGBP and zoledronate was antagonistic. To further assess the effects of the 
bisphosphonates, we analyzed annexin V and PI staining via flow cytometry and found that 
DGBP induced apoptosis more potently than zoledronate. Western blots show that DGBP 
treatment altered expression and membrane affinity of some but not all geranylgeranylated small 
GTPases, activated caspases, and increased ERK phosphorylation. Importantly, the anti-
proliferative effects of DGBP were blocked by treatment with a caspase inhibitor and by 
treatment with a MEK inhibitor. Together, our findings indicate that DGBP is a more potent and 
selective compound than zoledronate in inducing apoptosis mediated through pathways that 
include caspases and MEK/ERK. These findings support the further development of GGDPS 
inhibitors as anticancer therapeutics. This chapter was adapted from a previous publication 




Bisphosphonates are used widely for treatment of osteoporosis and other indications 
related to bone and calcium metabolism (Russell and Rogers, 1999, Licata, 2005, Russell et al., 
2008). These compounds are structural analogs of diphosphates that are resistant to metabolism 
because they contain a carbon atom in place of the connecting oxygen atom normally found in 
the diphosphate (Martin et al., 1999, Licata, 2005). The bisphosphonate structure is critical for 
binding to the active sites of pharmacological targets including the enzyme farnesyl diphosphate 
synthase (FDPS) (Cheng and Oldfield, 2004, Guo et al., 2007). At the same time, the 
bisphosphonate structure impacts the pharmacokinetics of these drugs as it has a strong affinity 
for binding to calcium, thus promoting bone distribution (Ebetino et al., 2011). These 
compounds primarily function by inhibiting cellular functions in the bone microenvironment. 
This is especially important for osteoporosis therapy, because bisphosphonates can reduce 
osteoclast-mediated bone resorption and ultimately strengthen bone density (Roelofs et al., 2006, 
Russell et al., 2008). 
Because of its activity in the bone microenvironment, the 3rd generation bisphosphonate 
zoledronate also has become useful for treatment of metastatic bone disease associated with solid 
tumors (Body, 2006, Stresing et al., 2007, Clezardin et al., 2011, Gnant, 2012) as well as 
multiple myeloma (Aparicio et al., 1998, Baulch-Brown et al., 2007, Guenther et al., 2010, 
Terpos et al., 2014, Tsubaki et al., 2015). It is thought that zoledronate functions to reduce the 
cellular intermediates of isoprenoid biosynthesis including farnesyl diphosphate (FPP) and 
geranylgeranyl diphosphate (GGPP), which are required for cell proliferation (Figure 5) (Reszka 
and Rodan, 2004, Okamoto et al., 2014). This disrupts protein geranylgeranylation, a process 
often required for malignant cell growth (Philips and Cox, 2007, Palsuledesai and Distefano, 
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2015, Sjogren et al., 2007). However, the mechanisms by which depletion of isoprenoids in 
transformed cells inhibits proliferation remain unclear. Additionally, the possibility remains that 
zoledronate or other bisphosphonates may also be used for other malignancies which have bone 
complications, such as acute T lymphocytic leukemia (Nishida et al., 2003, Kimura et al., 2004, 
Segawa et al., 2005, Ohtsuka et al., 2005, Chuah et al., 2005, Ishikawa et al., 2007). 
Bisphosphonates may ultimately be beneficial for leukemia therapy because leukemia 
patients frequently experience bone pain due to accumulation of the leukemia cells in the bone 
and joints (Ishikawa et al., 2007). Additionally, a substantial number of patients experience 
hypercalcemia, in particular those with leukemias derived from T cells (Kiyokawa et al., 1987). 
Therefore, bisphosphonates may offer two disease modifying mechanisms to T-cell leukemia- 
direct inhibition of leukemia cell proliferation that results from their inhibition of isoprenoid 
biosynthesis (Ishikawa et al., 2007) and relief from hypercalcemia that results from their binding 
to calcium ions (Ebetino et al., 2011).  
While the clinically-used bisphosphonates inhibit the enzyme FDPS (Amin et al., 1992, 
Rogers et al., 1994, Rogers et al., 1995, Luckman et al., 1998, van Beek et al., 1999b), we have 
recently explored a new class of bisphosphonates including DGBP (Figure 5), which target the 
subsequent enzyme in the mevalonate pathway (Wiemer et al., 2009), GGDPS (Shull et al., 
2006, Wiemer et al., 2007, Wiemer et al., 2011). The downstream molecular target affords the 
opportunity to retain the anti-proliferative characteristics of zoledronate which can result from 
depletion of GGPP while reducing potential side effects that may occur from depletion of FPP. 
Here, we evaluate the efficacy by which these two classes of bisphosphonates induce cell death 
in T lymphocytic leukemia and provide insights into the mechanisms through which depletion of 




DGBP inhibits proliferation of lymphocytic leukemia cell lines more potently than zoledronate  
We first compared the effects of two nanomolar inhibitors: zoledronate (a potent clinical 
inhibitor of FDPS (Kavanagh et al., 2006b)) and DGBP (a specific experimental inhibitor of 
GGDPS (Wiemer et al., 2007)) on the proliferation of T-cell leukemia lines. Treatment of either 
Molt-4 or Jurkat cells with varied concentrations of either compound for 72 hours dose-
dependently inhibited cell proliferation (Figure 6A/B). In both the Molt-4 and Jurkat cell lines, 
the anti-proliferative effect of DGBP was stronger than that of zoledronate (half-maximal 
inhibitory concentration (IC50) of DGBP = 15 μM in Molt-4 cells and 30 μM in Jurkat cells, IC50 
of zoledronate = 52 μM in Molt-4 cells and 81 μM in Jurkat cells) (Table 1). Both compounds 
were more potent against proliferation of these lymphocytic cell lines compared to myeloid 
leukemias, for which concentrations above 100 μM were required (Tsubaki et al., 2013). This 
surprising effect suggests that lymphocytic leukemias are more sensitive to isoprenoid depletion 
relative to myeloid leukemias and that inhibition of GGDPS is more anti-proliferative than 
inhibition of FDPS. 
Zoledronate but not DGBP decreases viability of primary PBMCs 
To determine whether the compounds have preferential effects on viability of malignant 
versus normal cells, we tested zoledronate and DGBP for toxicity against primary human 
peripheral blood mononuclear cells (PBMCs). In contrast to the pattern observed in the leukemia 
cell lines, zoledronate exhibited a stronger cytotoxic effect against the primary cells than DGBP 
(Figure 6C). The 72 hour IC50 of zoledronate against PBMCs was 63 μM while the IC50 for 
DGBP was 1200 μM. A therapeutic index was determined for each drug by calculating the ratio 
of the IC50 values in the leukemia cell lines versus PBMCs (Table 1), which demonstrates that in 
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contrast to zoledronate, which offers no selectivity, DGBP is much more selective (80 to 40 fold) 
against actively proliferating leukemia cells over resting primary blood cells. This finding also 
suggests that inhibition of FDPS by zoledronate results in cytotoxic effects in addition to the 
anti-proliferative effects caused by its depletion of GGPP. 
GGPP is required for proliferation 
To confirm target engagement in these cells, we performed add-back experiments by 
treatment of the cells with either of the two bisphosphonates for 72 hours in the presence or 
absence of exogenous GGPP or FPP. As expected, co-treatment with GGPP fully prevented the 
anti-proliferative effect of the GGDPS inhibitor, DGBP, whereas FPP did not. In these cells, 
treatment with GGPP resulted in a partial rescue of the zoledronate anti-proliferative effect, as 
did FPP (Figure 6D). Thus, zoledronate exerts its anti-proliferative effects in part via depletion of 
GGPP.  
The combination of DGBP and zoledronate is antagonistic in Molt-4 cells 
To determine if the combination of DGBP and zoledronate more strongly inhibits 
proliferation of Molt-4 cells, we treated cells for 72 hours with varied doses of the two 
compounds in a constant ratio determined by their respective potencies. Previously, in the K562 
myeloid leukemia line we observed weak synergy between the two compounds (Dudakovic et 
al., 2008). However, in the Molt-4 T-cell leukemia line we observed strong antagonism with this 
combination (Figure 6E/F). Here, the combination index values at the experimental 
concentrations ranged from 2-5 (Table S1). Therefore, the use of dual inhibitors of the FDPS and 




DGBP treatment alters protein expression and membrane association of RhoA, Rac and Rap1 
but not Cdc42 
We examined the effect of DGBP on levels of and membrane localization of a panel of 
geranylgeranylated proteins including RhoA, total Rac, Cdc42, and Rap1 (Figure 7A/B). Ras, 
expected to be predominately farnesylated, was used as a control. Treatment with DGBP 
increased protein expression of RhoA and Rap1 and decreased expression of total Rac (Figure 
7C). These changes in protein expression caused by DGBP were prevented by co-incubation 
with GGPP. DGBP did not alter Cdc42 and Ras protein expression (Figure 7C). Treatment with 
zoledronate increased the expression of RhoA, which could not be rescued by GGPP co-
incubation (Figure 7D). Zoledronate treatment did not appear to alter levels of Rac and Rap1. 
As expected, a significant fraction of RhoA, Rac, Rap1 and Ras was membrane 
associated (Figure 7A/B). Cdc42 was primarily cytosolic. DGBP treatment increased the ratio of 
cytoplasmic to membrane-associated RhoA, Rac, and Rap1 but not Ras (Figure 7E). In DGBP-
treated cells, this change in RhoA and Rap1 resulted from increased total protein which 
accumulated in the cytosolic fraction. However, the change in Rac localization was driven by 
decreased total protein levels which also were decreased in the membrane fraction (Figure 7G). 
The changes in Rac, RhoA, and Rap1 localization induced by DGBP treatment were restored 
upon co-incubation with GGPP. 
Treatment with zoledronate altered Rap1 and Ras cytosolic to membrane ratios (Figure 
7F). Although zoledronate reduced GGPP levels as evidenced by its effects on Rap1, zoledronate 
did not alter the cytosolic to membrane ratios of Rac or RhoA. Interestingly, zoledronate caused 
Cdc42 to be localized in the membrane while DGBP did not have that effect (Figure 7H). Co-
incubation with GGPP restored the effect of zoledronate on Rap1 and Ras. Taken together, 
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treatment with DGBP broadly affects the expression and localization of geranylgeranylated 
proteins and does so with a different pattern of activity than zoledronate.  
DGBP-induced inhibition of proliferation is not mediated by geranylgeranylated RhoA 
This pattern of GTPase regulation in response to DGBP treatment initially led us to 
hypothesize that the anti-proliferative effects of DGBP were mediated by its effects on RhoA. 
We asked whether or not overexpression of RhoA could prevent the anti-proliferative effect of 
DGBP (Figure 8A). We expressed exogenous WT-RhoA and found it was unable to restore the 
anti-proliferative effect of DGBP. Because the plasmid WT-RhoA would also be 
geranylgeranylated and blocked by DGBP, we also expressed a mutated RhoA in which the 
CAAX motif (Hougland et al., 2009) was replaced with one signaling farnesylation (CVLS). 
Again, farnesylated RhoA was unable to block the anti-proliferative effects of DGBP, as DGBP 
decreased proliferation of cells transfected with RhoA-CVLS as well as those transfected with 
the pcDNA3.1+ (empty vector) (Figure 8A).  
As it has been reported that active cytosolic RhoA can mediate effects of isoprenoid 
depletion in some systems (Zhu et al., 2013), we tested whether inhibition of Rho affects DGBP 
activity. Treatment with a cell permeable C3 transferase, which inhibits Rho activity and has low 
affinity for Cdc42 and Rac, had no effect on the proliferation in the presence of DGBP or GGPP 
(Figure 8B). Taken together, this implies that a Rho GTPase, including RhoA, is not the primary 
GTPase involved in the anti-proliferative effects of DGBP in this model. 
DGBP decreases levels of active Rac  
Because we observed that DGBP treatment strongly decreased levels of membrane-
associated Rac (Figure 7), we assessed how DGBP treatment affects Rac activation as monitored 
by its GTP binding. We pulled down GTP-bound Rac1 using PAK1-conjugated GST beads and 
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determined levels of active GTP-bound Rac by Western Blot. GTP-bound Rac1 decreased with 
DGBP treatment (Figure 8C/D), and was restored to control levels with GGPP co-incubation, 
suggesting that GGPP depletion decreases the activity of Rac1. We found that NSC 23766, a 
Rac1 inhibitor, has similar effects on the proliferation as DGBP does (Supplemental Figure 1). 
Taken together, DGBP treatment reduces Rac1 expression, localization, and GTP binding.  
DGBP induces apoptosis more potently than zoledronate 
To determine whether the anti-proliferative effects of these bisphosphonates resulted 
from increased apoptosis, we analyzed annexin V and propidium iodide (PI) staining. Cells were 
treated with DGBP or zoledronate for 72 hours at varied concentrations. Both compounds 
increased the percentage of cells in late apoptosis (annexin V+/PI+) but not early apoptosis 
(annexin V+/PI-) (Figure 9A). Consistent with the proliferation experiments, DGBP was also 
more potent than zoledronate for induction of apoptosis, with a statistically significant difference 
observed when cells were treated with 30 μM of either agent (Figure 9A). In these experiments, 
co-incubation with GGPP rescued the ability of both bisphosphonates to induce late apoptosis 
(Figure 9B). FPP did not rescue the effect of DGBP, but did partially rescue zoledronate (Figure 
9C). 
Additionally, induction of apoptosis was examined by Western Blot analysis for the 
appearance of caspase 3 and caspase 7 cleavage products (Figure 10A/B). DGBP markedly 
increased both cleaved caspase 3 and caspase 7 at concentrations of 10 μM and 30 μM. In 
contrast, zoledronate treatment did not cause cleaving of these caspases at equivalent 
concentrations. However, zoledronate at 100 μM did induce cleaved caspase, but the magnitude 
of this effect was less than that of DGBP at significantly lower concentrations. Caspase 
activation by both bisphosphonates was prevented by co-incubation with GGPP (Figure 10C). 
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Next, we assessed whether the caspase activation was responsible for the anti-proliferative effect 
of DGBP. To this end, we treated cells with DGBP in the presence or absence of the pan-caspase 
inhibitor zVAD-FMK (Figure 10D). Again, DGBP dose- dependently inhibited proliferation 
which was fully blocked by co-incubation with the caspase inhibitor. Taken together, the 
mechanism by which DGBP and zoledronate reduce proliferation is by induction of caspase-
mediated apoptosis, with DGBP exhibiting greater potency. 
DGBP-induced apoptosis is mediated by ERK activation 
Because a prior study had suggested that depletion of isoprenoids following treatment 
with an HMG-CoA reductase inhibitor led to alterations in kinase activity (Qi et al., 2013), we 
investigated the mechanism by which DGBP induces apoptosis by performing Western Blot 
analysis to detect phosphorylation of the mitogen activated protein kinases ERK, p38 kinase, and 
JNK. We were unable to detect any changes in phosphorylation of p38 or JNK (not shown), 
however treatment with DGBP increased phosphorylated ERK, which was prevented by addition 
of exogenous GGPP (Figure 11A/B). The increase in ERK phosphorylation was apparent at 10 
and 30 μM concentrations of DGBP and 100 μM zoledronate, consistent with concentrations that 
induced caspase cleavage for both compounds. Additionally, co-incubation of GGPP with DGBP 
decreases levels of phosphorylated ERK (Figure 11A). 
We next assessed whether DGBP-induced ERK phosphorylation could be blocked by 
PD98059, a MEK inhibitor. The induction of ERK phosphorylation by DGBP decreased by co-
incubation with PD98059 (Figure 11C), demonstrating that MEK mediates DGBP-induced ERK 
phosphorylation. At the same time, ERK phosphorylation appears not to be upstream of caspases 
as the MEK inhibitor did not prevent the effect of DGBP on caspase cleavage (Figure 11C). To 
further assess the order of activation, we tested whether caspase inhibition would affect ERK 
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phosphorylation (Figure 11D). Again, cells treated with DGBP displayed high levels of cleaved 
caspase which was blocked by co-incubation with zVAD-FMK. DGBP-induced ERK 
phosphorylation was not altered by co-treatement with zVAD-FMK. This finding suggests that 
MEK activation leading to ERK phosphorylation is not downstream of caspase activation. 
We then tested whether ERK phosphorylation was required for inhibition of proliferation 
and induction of apoptosis by DGBP. We treated cells with DGBP in the presence or absence of 
PD98059. As a single agent, PD98059 did not affect the cells at concentrations up to 100 μM for 
72 h in either the proliferation or apoptosis assays. However, PD98059 was able to partially 
rescue the anti-proliferative effect (Figure 11E) and the pro-apoptotic effect of DGBP (Figure 
11F). Therefore, MEK activity and ERK phosphorylation appears to contribute to DGBP-
induced apoptosis. 
Rac1 is partially involved in DGBP-mediated effects on viability 
To determine whether DGBP-induced apoptosis relied more on RhoA or Rac1, we treated Molt-
4 cells with NSC 23766, a Rac1 inhibitor, and Y-27632, a ROCK inhibitor. Treatment of Molt-4 
cells with Rac1 inhibitor alone has no significant change with untreated cells. More importantly, 
NSC treatment in combination with DGBP increases the proliferation of Molt-4 beyond that of 
DGBP treatment alone (Figure S2). Thus, Rac1 inhibition interrupts the anti-proliferative effect 
of DGBP. The same ROCK inhibitor and Rac1 inhibitor conditions were used inhibitors were 
used with DGBP with no significance the DGBP-treated or DGBP and ROCK inhibitor treated 
conditions. Interestingly, DGBP treatment increased levels of active cdc42 which were 
ameliorated with GGPP addback (Figure S2). To test whether the PI3K pathway was involved, 
we investigated levels of phosphorylated Akt with DGBP treatment. DGBP decrease 
phosphorylated Akt, ableit only slightly (Figure S3). We further tested an MEK1/2 and ERK1/2 
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dual inhibitor, AZD-6244, and found that it robustly rescued DGBP induced apoptosis in the 
Molt-4 cells but not in the Jurkat cells (Figure S4). Overall, Rac1 is partially involved in DGBP-
mediated decrease in cell viability. 
Discussion 
Here, we have demonstrated that zoledronate and DGBP inhibit proliferation of T-cell 
leukemia cells via blocking the intermediate enzymes of the mevalonate pathway. This leads to 
depletion of cellular GGPP, alterations in protein geranylgeranylation and expression, activation 
of caspases, and pro-apoptotic signaling through ERK. However, these two bisphosphonates, 
which have different molecular targets, differ in their potency, selectivity, and their effects on 
geranylgeranylated proteins. 
DGBP inhibits proliferation and induces apoptosis at lower concentrations than 
zoledronate, which is consistent with results observed in a prostate cancer model, where DGBP 
also was more potent (Wasko et al., 2011). These results are surprising because zoledronate is 
approximately 10 fold more potent against purified FDPS than is DGBP against purified GGDPS 
(Wiemer et al., 2007). We believe the different pattern in cellular activity is a result of a 
combination of two factors- 1) higher lipophilicity of DGBP relative to zoledronate which 
enhances access to the cellular enzymes and 2) decreased ability of cells to overcome GGDPS 
versus FDPS inhibition (Wiemer et al., 2011). While both compounds are active in cells in the 
micromolar range, bisphosphonates achieve locally high bone concentrations which enable their 
effects in vivo (Fournier et al., 2008, Fournier et al., 2010). 
Initially, we hypothesized that increased cellular potency of DGBP relative to zoledronate 
was due higher permeability compared to zoledronate. However, if cell permeability were the 
major issue underlying activity, then one might see a similar pattern of activity in the primary 
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PBMCs. But this pattern is reversed in PBMCs, with zoledronate being more toxic relative to 
DGBP. This finding argues that the differences in activity between the two compounds results 
from mechanistic differences caused by inhibition of their respective targets. Indeed, one 
advantage of targeting GGDPS is that its inhibition cannot be readily overcome by increased 
isoprenoid flux (Wiemer et al., 2011). 
GGDPS inhibitors have two immediate effects- depletion of the product GGPP and 
elevation of the reactants isopentenyl diphosphate and FPP. In myeloid leukemia cells, we 
previously observed that co-incubation with GGPP was unable to mitigate all of the effects of 
DGBP and that elevated levels of FPP can contribute to the anti-proliferative mechanism 
(Dudakovic et al., 2008). This differs from the current study in which the effects of DGBP were 
fully rescued by GGPP. Furthermore, the apoptotic effect of DGBP could not be rescued by FPP. 
Interestingly, the apoptotic effect of zoledronate was only partially rescued by FPP and was 
nearly fully rescued by GGPP. Taken together, the apoptotic effects of DGBP and zoledronate in 
these cells are primarily due to GGPP depletion. Because FPP only partially rescued the effects 
of zoledronate, it is possible that zoledronate may affect GGDPS at high cellular concentrations. 
In a previous study, zoledronate did not inhibit purified GGDPS up to 10 μM (Wiemer et al., 
2007). We predict that cell permeability is a barrier for entry resulting in lower increllular levels 
than are found in the media, but we cannot exclude the ability of zoledronate at 100 μM to inhibit 
GGDPS, especially given that GGPP rescues its apoptotic effect.  
We observed membrane populations of Rac, RhoA and Rap1 but not Cdc42. GGDPS 
inhibition increased the cytosolic: membrane ratio of all of the membrane associated 
geranylgeranylated GTPases examined. Surprisingly, although zoledronate increased the 
cytosolic: membrane ratio of both Ras and Rap1, it did not significantly alter Rac or RhoA in this 
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manner, in contrast to a prior report that showed zoledronate caused cytoplasmic Rho 
accumulation (Chaplet et al., 2004). We found it interesting that Rac and Rho were only altered 
by DGBP. While it appears that the effect on Rap1 exceeds the effect on Rac and Rho, there is 
little Rap1 in the cytosol of untreated cells and nearly no change in the in the membrane fraction. 
In fact, of all the proteins examined, only the membrane fraction of Rac in response to DGBP 
was decreased, while the other proteins increased their cytosolic fractions. Although membrane 
association is not always a prerequisite for activity, it is commonly required for activity and its 
disruption is desirable (Cox et al., 2015, Mohammed et al., 2016, Hahne et al., 2012). Ultimately, 
the localization of many small GTPases was altered with either compound, indicative of 
engagement with their respective targets. Interestingly, DGBP treatment altered total expression 
of Rac, RhoA, and Rap1, albeit in different ways, with Rac expression decreased and RhoA and 
Rap1 expression increased. Clearly, different pathways must regulate the expression of these 
proteins. 
Given the effects of DGBP on numerous geranylgeranylated proteins, we found it 
difficult to assess which specific GTPase, if any, is responsible for inhibition of proliferation. We 
predicted that RhoA was involved as the bulk of the literature suggests it often mediates 
proliferation (Agabiti et al., 2016), and a well-constructed study showed farnesylated RhoA 
rescued the effect of GGTase I depletion (Sjogren et al., 2007), but none of the Rho GTPases 
were involved in the anti-proliferative effects of DGBP. As an alternative, the Rac1 inhibitor 
caused a decrease in proliferation at a concentration similar to that of DGBP. Although NSC 
23766 does not activate ERK (Figure S1), Rac may still be involved in DGBP-mediated 
apoptosis, as others have seen Rac1 is required for proliferation in response to GGTase I 
overexpression (Zhou et al., 2013). 
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How then, does DGBP lead to apoptosis? We hypothesized that MAPK signaling might 
be affected by changes in protein geranylgeranylation, and found that levels of phosphorylated 
ERK were altered by DGBP and, to a lesser extent, zoledronate. Therefore, to investigate the 
ERK pathway as a mechanism of apoptosis, we focused on DGBP, which increased ERK 
phosphorylation by several fold. This increase in ERK phosphorylation is in contrast to the effect 
seen in AML as proliferation is blocked by lovastatin and is dependent upon decreased ERK 
phosphorylation (Wu et al., 2004). There is some precedent for ERK involvement in apoptosis 
since ERK mediates apoptosis caused by cisplatin (Wang et al., 2000). While we could not 
establish a causal relationship between p-ERK and caspase, our data that shows DGBP-mediated 
apoptosis is partially rescued by a MEK inhibitor, suggesting that ERK involvement in apoptosis 
is late in the stages of apoptosis. Depleting GGPP alters GTPase localization which cleaves 
caspases leading to apoptosis and phosphorylates ERK also leading to cell death. 
In conclusion, in order to use bisphosphonates to best achieve direct anticancer effects in 
the bone environment, the general strategy of targeting GGDPS likely compares well to targeting 
FDPS, which is exemplified by increases in cellular potency and selectivity of DGBP versus 
zoledronate. DGBP works by inhibiting prenylation of some small GTPases which leads to 
changes in their expression, caspase cleavage, MEK activation, ERK phosphorylation, and 
apoptosis. Thus, GGDPS inhibitors such as DGBP may produce greater single-agent anti-
proliferative effects relative to zoledronate. Additionally, future studies should examine whether 
GGDPS inhibitors or their prodrugs (Wiemer and Wiemer, 2015) may be a viable strategy to 
targeting diseases in which Rac plays a role, given the strong reduction in Rac expression, 
membrane localization, and GTP binding seen with DGBP treatment. 
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Materials and Methods 
Cells and reagents 
The T-cell leukemia lines Molt-4 and Jurkat were obtained from ATCC (Manassas, VA). 
Human peripheral blood mononuclear cells were purified from whole blood obtained from 
Research Blood Components (Boston, MA) (Hsiao et al., 2014). Annexin-V FITC and propidium 
iodide were obtained from BD Biosciences (San Jose, CA) and eBioscience (San Diego, CA). 
GGPP and FPP were obtained from Cayman Chemical (Ann Arbor, MI). AZD-6244 was 
obtained from APEX Bio (Houston, TX, USA) Zoledronate was obtained from Fisher (Rockford, 
IL). DGBP was a kind gift from Dr. David Wiemer at the University of Iowa. FBS and other 
tissue culture supplies were obtained from Thermo Fisher. CellQuantiBlue was obtained from 
BioAssay Systems (Hayward, CA). zVAD-FMK was obtained from ApexBio (Houston, TX). 
PD98059 was obtained from LC Labs (Woburn, MA). C3 transferase was obtained from 
Cyotoskeleton (Denver, CO). Antibodies to ERK (L34F12) pERK (D13.14.4E), cleaved caspase 
3 (5A1E), cleaved caspase 7 (D6H1), RhoA (67B9), Rac1/2/3 (polyclonal #2465), p-Akt 
(Ser473) (D9E) and Cdc42 (11A11) were obtained from Cell Signaling Technology (Danvers, 
MA). The antibody for beta-actin (Poly6221) was obtained from Biolegend. The anti-tubulin 
(E7) antibody developed by Michael Klymkowsky was obtained from the Developmental 
Studies Hybridoma Bank at The University of Iowa. pGEXTK-Pak1 70-117 was obtained from 
Addgene (Cambridge, MA). 
Proliferation/viability assay 
Assays were performed as described previously (Wiemer et al., 2013, Oblak et al., 2014, 
Li et al., 2016). Briefly, 10,000 cells/well of Molt-4 or Jurkat cells in log phase growth or 
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100,000 cells/well of PBMCs were added to 96-well plates in 100 μL in the presence of test 
compounds and fresh media. Cells were cultured for 72 hours. During the last 2 hours, cells were 
labeled with 10 μL of CellQuantiBlue reagent, and were scanned with a Victor plate reader 
(ex550/em600). 
Analysis of apoptosis 
Annexin V and PI analysis was performed according to manufacturer protocol (BD 
Biosciences) as described (Dudakovic et al., 2008). Treated cells were transferred to 
microcentrifuge tubes, centrifuged at 600 x g for 3 minutes, and then the supernatant was 
aspirated. Cells were resuspended in 100 μL of binding buffer (10 mM HEPES, 150 mM NaCl, 1 
mM MgCl2, 5 mM KCl, and 1.8 mM CaCl2, pH 7.4) then transferred to polystyrene test tubes. 
Three microliters of FITC annexin V was added, and the cells were incubated for 15 minutes on 
ice. Two microliters of 50 µg/mL PI solution (Sigma-Aldrich, St. Louis, MO) was added to the 
cell suspension, and the suspension was mixed and analyzed using a FACSCalibur (BD 
Biosciences, Franklin Lakes, NJ). 
Triton X-114 Separation 
Membrane and cytosolic fractions were purified as described previously with some 
modifications (Bordier, 1981, Wasko et al., 2011). Briefly, cells were resuspended in media at a 
concentration of 0.75 million cells/mL and cultured for 48 hours with indicated concentrations of 
compounds or solvent controls. Cells were then spun at 600 x g for 3 minutes, washed with PBS, 
and resuspended in Triton X-114 lysis buffer (20 mM Tris pH 7.5, 150 mM NaCl, 1% Triton X-
114) containing freshly added protease and phosphatase inhibitors including leupeptin (1μg/mL), 
aprotinin (1μg/mL), pepstatin (1μg/mL), and PMSF (200 μM). Lysate was passed through a 27-
gauge needle and centrifuged for 15 minutes at 12,000 x g at 4°C. The resulting supernatant was 
38 
 
transferred to a new tube and incubated at 37°C for 10 minutes in a water bath. Following 
incubation, the lysate was centrifuged for 12,000 x g for 2 minutes at room temperature. 
Aqueous phase (upper) was transferred to a new tube and detergent phase (bottom) was diluted 
with excess buffer. 
Western Blot Analysis 
Cells were resuspended in fresh media at a concentration of 0.5 million cells/mL. Cells 
were cultured for 72 hours with indicated concentrations of test compounds or solvent controls. 
Cells were washed once in PBS and resuspended in lysis buffer (25 mM Tris–HCl pH 7.6, 150 
mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) for 10 minutes on ice followed by 
centrifugation for 10 minutes at 10,000 x g. Lysis buffer contained a panel of freshly added 
protease and phosphatase inhibitors including leupeptin (1μg/mL), aprotinin (1μg/mL), PMSF 
(200 μM), sodium vanadate (200 μM), sodium pyrophosphate (10 μM), sodium fluoride (50 
μM), and glycerophosphoric acid (10 μM) (all from Fisher). Proteins were quantified by BCA 
assay and equivalent masses were loaded onto 10% or 15% SDS-PAGE gels for separation. 
Proteins were transferred to nitrocellulose membranes and blotted with pERK, ERK, RhoA, 
Rac1, Cdc42, Rap1, pan-Ras, cleaved caspase 3, or cleaved caspase 7 antibodies. Proteins were 
visualized using a Licor Odyssey. Alexa-Fluor 680 goat-anti-mouse IgG and IRDye 800CW 
goat-anti-rabbit IgG were used for detection. Tubulin or beta-actin were used as a loading 
controls. 
Rac1/cdc42 pulldown assay 
E. coli (BL21) were transformed with pGEXTK-Pak1 70-117. 50 mL cultures in LB-
AMP were grown for 14 hours. The culture was transferred to a flask of 750 mL of LB broth and 
treated with IPTG (1 mM) for 5 hours. Cells were pelleted by centrifugation and resuspended in 
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25 mL of lysis buffer (50 mM sodium phosphate, 300 mM NaCl, pH 8.0 with PMSF, aproptinin, 
leupeptin, pepstatin). The lysate was passed through a French press twice. The lysate was then 
allowed to bind to glutathione agarose beads overnight at 4º C (Pierce Thermo Scientific). GST 
beads were washed with equilibration buffer (50 mM Tris, 150 mM NaCl, pH 8.0) and stored at -
80º C. Molt-4 cells were lysed according to the Western blotting protocol and the lysate was 
rotated at 4º C for 45 minutes. Beads were washed with equilibration buffer twice. Western blot 
procedure was implemented as described above.  
Combination Index Analysis 
Isobolograms were generated using Calcusyn software (Biosoft, Cambridge, UK). 
Combination index (CI) values were calculated according to the method of Chou and Talalay as 
described in the manual (Chou and Talalay, 1984). For each drug, 72-h IC50 values were 
determined by CellQuantiBlue assay. Concentration-response curves were generated for each 
compound and combination using four 80% dilutions.  
RhoA overexpression 
Human RhoA was amplified by PCR using the following primers designed to yield a C-
terminal faneslyation sequence (-CVLS): 5’-GCT ATC GAA TTC ATG GCT GCC ATC CGG 
AAG A-3’ (forward) and 5’-GCT ATC CTC GAG TCA GCT CAG CAC GCA ACC AGA TTT 
TTT CTT CCC A-3’ (reverse). The amplicon was ligated into the pcDNA3.1(+) plasmid using 
the EcoRI and XhoI restriction sites. Prior to electroporation, Molt-4 cells were incubated 
overnight without antibiotics. Cells were then washed and resuspended in serum free media at 
2.5 x 107 cells/mL. 20 μg of DNA was added to 400μL of cells for 10 minutes at RT. Cells were 
pulsed using the exponential protocol at 316 V and 500 μF and allowed to incubate at RT for 15 




ANOVA (one-way) was used to calculate significance. Comparisons were done relative 
to the control or between pairs of conditions as indicated in the graphs. Columns in bar and line 
graphs represent the mean +/- standard deviation of the indicated number of experimental 






Figure 5. Biosynthesis of GGPP and known isoprenoid biosynthesis pathway 
inhibitors.  
Bisphosphonates such as zoledronate and DGBP inhibit isoprenoid biosynthesis by targeting the 
enzymes FDPS and GGDPS, respectively. Isopentenyl diphosphate isomerase (IDI) catalyzes the 
isomerization of isopentenyl diphosphate (1) into DMAPP (2). FDPS then takes one equivalent 
of DMAPP and two equivalents of isopentenyl diphosphate to form FPP (3). This step can be 
inhibited by zoledronate (5). Geranylgeranyl diphosphate synthase (GGDPS) then catalyzes the 
condensation of FPP and isopentenyl diphosphate to form GGPP (4). This step can be inhibited 







Figure 6. DGBP and zoledronate inhibit proliferation of malignant T lymphocytic 
cells through depletion of GGPP.  
A-C) Dose response curves for Molt-4 and Jurkat cells, and PBMC, treated with either DGBP or 
zoledronate. Cells were incubated for 72 hours with compound. * indicates significant difference 
between the two compounds at the indicated drug concentration. D) Growth inhibition caused by 
DGBP is rescued by co-treatment with GGPP, and not rescued by FPP, while zoledronate is 
partially rescued by co-treatment with either GGPP or FPP. E) Proliferation of Molt-4 cells with 
DGBP in combination with zoledronate. F) Isobologram of DGBP with zoledronate. * indicates 
significant difference with respect to untreated control. # denotes significant difference from 
treatment with bisphosphonate alone. Statistical significance determined by ANOVA with 







Figure 7. DGBP alters membrane levels of Rac but not RhoA or Cdc42.  
A) Western blot of Rac1/2/3, RhoA, Cdc42, Rap1, and pan-Ras in Molt-4 cells treated with 
DGBP. “W” represents whole cell lysate, “C” represents the cytosolic fraction, and “M” 
represents the membrane fraction. B) Western blot of RhoA, Rac1/2/3, Cdc42, Rap1 and pan-
Ras in Molt-4 cells treated with zoledronate and co-incubated with GGPP. C) Quantification of 
whole cell lysate fractions of small GTPases with DGBP. C) Whole cell lysate fractions of small 
GTPases with zoledronate. D) Cytosolic fractions vs. membrane fractions of cells treated with 
DGBP. D) Ratio of cytosolic fractions: membrane fractions of cells treated with zoledronate. E)  
Quantification of membrane fractions of Molt-4 cells treated with DGBP and GGPP on left and 
F) zoledronate and GGPP on right. All data represented as mean ± SD, n=3, *p<0.05 by 






Figure 8. Neither Rho nor Rac is responsible for mediating the anti-proliferative 
effect of DGBP.  
A) Farnesylated RhoA does not bypass the effect of DGBP. 72 hour proliferation of transfected 
Molt-4 cells. pcDNA3.1 represents the empty vector. Cells were treated with DGBP alone and 
DGBP with GGPP. B) Cells were treated with C3 transferase alone and in combination with 
DGBP and GGPP for 72 hours. Proliferation is determined by CellQB assay. *indicates 
significance with respect to untreated control. # denotes significant difference from treatment 
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with bisphosphonate alone. C) Western blot analysis of activated Rac1 pull-down. “WCL” 
represents the whole cell lysate. D) Quantification of Western blot analyses of Rac1 (right). Both 
quantifications were compared to whole cell levels of GTPase. All data represented as mean ± 








Figure 9. DGBP and zoledronate induce late apoptosis through depletion of GGPP.  
A) Annexin V/PI staining of Molt-4 cells as determined by flow cytometry. Dose response of 
DGBP and zoledronate. Left: early apoptosis, right: late apoptosis. B) Bisphosphonates with co-
incubation of GGPP. Cells were incubated for 72 hours with various concentrations of 
bisphosphonate. Left: early apoptosis, right: late apoptosis. C) Bisphosphonates with co-
treatment of FPP. Left: early apoptosis, right: late apoptosis. All data represented as mean ± SD, 
n=3, * indicates significant difference with respect to untreated control conditions # indicates 
significant difference with respect to bisphosphonate treated conditions. ‡ denotes significant 
difference between indicated populations. Statistical significance determined by ANOVA with 






Figure 10. DGBP and zoledronate-mediated apoptosis is through caspase 3 and 7 
cleavage.  
A) Western blot of cleaved caspase 3/7 in Molt-4 cells with bisphosphate treatment. B) Caspase 
3/7 cleavage is greater with DGBP than zoledronate. C) Caspase cleavage is rescued by co-
incubation with GGPP. D) Proliferation of Molt-4 cells in presence of different concentrations of 
DGBP and 100 μM zVAD-FMK (pan-caspase inhibitor). In A, B, C, all data represented as 
mean ± SD, n=3, * indicates significant difference with respect to untreated control conditions. ‡ 
denotes significant difference between indicated populations. Statistical significance determined 
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Figure 11. DGBP-mediated apoptosis is partially dependent on ERK.  
A) Western blot showing ERK phosphorylation in Molt-4 cells treated with bisphosphonates. 
Data is representative of three independent experiments. B) ERK phosphorylation is dose-
dependently increased by DGBP. The effect is greater with DGBP than with zoledronate. C) 
Western blot analysis of p-ERK, ERK, cleaved caspase 3 and 7 in response to DGBP and PD 
98059. D) Western blot analysis of p-ERK, ERK, and cleaved caspase 3 and 7 in response to 
DGBP and zVAD-FMK treatment. E) Molt-4 proliferation with DGBP and PD 98059 (MEK 
inhibitor) treatment via viability assay. F) Molt-4 apoptosis with DGBP and PD 98059 treatment 
via flow cytometry. Annexin V+ and PI- represented by early apoptosis. Annexin V+ and PI+ 
represented by late apoptosis. All data in B, E, and F represented as mean ± SD, n=3. * indicates 
significant difference with respect to untreated control conditions. # indicates significant 
difference with respect to bisphosphonate-treated conditions. Statistical analysis done by 
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DGBP (μM) Zoledronate (μM) CI 
41 41 7.5 
51 51 6.9 
64 64 4.8 
80 80 3.9 
100 100 4.4 
 








Figure S1. Rac inhibitor decreases proliferation but does not alter ERK phosphorylation.  
 
A) Dose response of Rac inhibitor, NSC 23766, on proliferation of Molt-4 cells. Data is 
representative of five independent experiments B) Western blot analysis of p-ERK levels with 
NSC 23766 treatment. Data represents mean ± SD, n=3. * indicates significant difference with 





Figure S2. Rac1 inhibitor (NSC 23766) rescues the anti-proliferative effect of DGBP and DGBP 
increases levels of active cdc42.  
 
A) Cells were treated with NSC 23766 alone, Y-27632 and in combination with DGBP for 72 
hours. Proliferation is determined by CellQB assay. B) Western blot of PAK1-GST pull-down. 
“W” represents the whole cell lysate with GDP and GTP treated controls. “WCL” also represents 
the whole cell lysate input in treatment conditions. PAK1-GST represents pull-down conditions. 
58 
 
Quantification of pulldown shown below Western. *indicates significance with respect to 





Figure S3. DGBP activates Akt.  
 
A) Western blot analysis indicates increase in phosphorylated Akt upon treatment of DGBP (48 





Figure S4. MEK/ERK 1 and 2 inhibitor, AZD-6244, rescues the effect of DGBP on apoptosis in 
Molt-4 cells.  
 
A) Raw Annexin V and PI flow plots of Jurkat and Molt-4 cells treated for 72 hours with solvent 
control, AZD-6244, DGBP, and combination of AZD-6244 and DGBP.   
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CHAPTER 3. REGULATION OF THE NOTCH-ATM-ABL AXIS BY 
GERANYLGERANYL DIPHOSPHATE SYNTHASE INHIBITION 
 
Abstract 
Notch proteins drive oncogenesis of many cancers, most prominently in T-cell acute 
lymphoblastic leukemia (T-ALL). T-ALL, like many hematological malignancies, has high 
levels of DNA damage yet does not undergo DNA damage-induced apoptosis. We have 
identified and developed novel agents that induce apoptosis in T-ALL cells, which are selective 
inhibitors of the enzyme geranylgeranyl diphosphate synthase (GGDPS). Here, we show that 
GGDPS inhibition blocks Notch1 processing, preventing its transcriptional activity on c-myc and 
activating the DNA damage response. GGDPS inhibition circumvents the evasion of apoptosis 
through depletion of Notch1, activation of ataxia telangiectasia mutated kinase and of Abelson 
murine leukemia viral oncogene homolog 1 (ABL-1). Surprisingly, induction of apoptosis by 
GGDPS inhibition also is reduced by co-treatment with γ-secretase inhibitors. Inhibitors of γ-
secretase and ataxia telangiectasia mutated, but not of GGDPS or ABL-1, promote Notch mRNA 
stability. Our results furthermore show that c-abl inhibitors reduce the cytotoxicity of DNA-
damage inducing chemotherapy agents. These results provide a mechanism by which T-ALL 
cells use Notch1 to avoid DNA damage-induced apoptosis, which can be overcome by inhibition 
of GGDPS. 
Introduction 
 T-cell acute lymphoblastic leukemia (T-ALL) is a rare but aggressive T-cell 
malignancy. T-ALL comprises approximately 15% of childhood and 25% of adult ALL cases 
(Pui et al., 2004). While the 5-year survival rate in children (80%) has improved significantly 
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due to advances in chemotherapy, survival in primary resistant and relapsed cases is still low 
(Sanchez-Martin et al., 2017), and many current therapies often cause toxicity in healthy cells.  
One of the most mutated genes in T-ALL is NOTCH1, which is altered in over 60% of T-ALL 
cases (Weng et al., 2004). Notch is also mutated in other types of cancer, such as breast, colon, 
lung and prostate cancer (Brzozowa-Zasada et al., 2017). However, its role in cancer is context 
dependent because Notch is oncogenic in some models but functions as a tumor suppressor in 
others (Radtke and Raj, 2003). Notch signaling is evolutionarily conserved and is required at 
multiple points in the developmental process and in particular in T-cell development (Andersson 
et al., 2011, Passaro et al., 2016). Notch is first processed in the Golgi by furin convertases 
(Brzozowa-Zasada et al., 2017). It is then transported to the plasma membrane where under 
normal circumstances it encounters its ligand (delta/serrate/LAG-2) (Olsauskas-Kuprys et al., 
2013). Ligand binding promotes two cleavage events, one by Adam10 and the other by γ-
secretase (Gordon et al., 2007). It has been proposed that Notch activation cannot occur without 
γ-secretase processing. Hydrolysis by γ-secretase processing releases the active form of Notch, 
the Notch internal domain (NICD), which can translocate to the nucleus, bind to transcription 
factors, and promote proliferation and differentiation (Sanchez-Martin and Ferrando, 2017). 
 Recent findings suggest a role for small GTPases in Notch processing. Court et al. 
showed a requirement of Rab7 and Rab8 in Notch1 signaling (Court et al., 2017), while Doi et 
al. found that Rap1 is essential in maturation of Adam10 (Doi et al., 2015). At the same time, we 
identified selective inhibitors of the enzyme geranylgeranyl diphosphate synthase (GGPS1, or 
GGDPS), which can be used to disrupt the function of these small GTPases (Wiemer et al., 2011, 
Wiemer et al., 2007, Agabiti et al., 2017, Shull et al., 2006, Wiemer et al., 2008a, Wiemer et al., 
2008b). GGDPS is an enzyme in the isoprenoid biosynthesis pathway that produces 
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geranylgeranyl diphosphate (GGPP) whose lipid moiety is post-translationally attached to small 
GTPases such as Rab and Rap to promote membrane association (Agabiti et al., 2016). Thus, we 
hypothesized that disrupting small GTPase lipidation with a GGDPS inhibitor would affect 
Notch signaling and display beneficial growth inhibition in T-ALL. Because drugs such as 
statins and nitrogenous bisphosphonates deplete GGPP and are implicated as cancer therapeutics, 
it is important to understand the signaling pathways relevant to GGPP depletion. Throughout 
these studies we use an inhibitor of GGDPS, digeranyl bisphosphonate (DGBP), to directly 
deplete levels of GGPP. DGBP is not the most potent GGDPS inhibitor, as Haney et al. describes 
a GGDPS inhibitor with 30 nM cellular activity and Lacbay et al. with 0.14 μM activity against 
RPMI-8226 cells (Haney et al., 2018, Lacbay et al., 2018), DGBP has an IC50 of 200 nM and is 
well characterized making it useful for determining how GGPP depletion leads to apoptosis 
(Shull et al., 2006, Wiemer et al., 2007). Here, we describe the mechanism by which GGPP 
depletion downregulates Notch expression and function leading to apoptosis. 
Results 
Inhibition of GGDPS decreases expression of the Notch1 internal domain 
A recent report demonstrated Rab GTPases regulate Notch processing (Court et al., 
2017). Because Rab proteins are post-translationally geranylgeranylated, we asked whether or 
not geranylgeranylation inhibitors would affect Notch-dependent cells. We treated the T-ALL 
cell lines Molt-4 and Jurkat with the isoprenoid biosynthesis inhibitors lovastatin (HMG-CoA 
reductase), zoledronate (farnesyl diphosphate synthase), and digeranyl bisphosphonate or DGBP 
(Shull et al., 2006) (geranylgeranyl diphosphate synthase) to investigate the effect on cell 
viability. We also evaluated the γ-secretase inhibitor DAPT. Consistent with the literature (Rao 
et al., 2009, O'Neil et al., 2007), DAPT did not strongly impact cell viability (Figures 12A/B). In 
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contrast, both DGBP and lovastatin decreased cell viability with DGBP demonstrating the 
stronger effect. Zoledronate did not impact Molt-4 and Jurkat cell viability at concentrations up 
to 100 µM, even though it was more potent than DGBP in the osteosarcoma cell line U2OS, with 
activity at 10 µM (Supplementary Figure S5). 
Because Notch is a critical oncogene, which drives proliferation of T-ALL cells, we 
evaluated these compounds in Western blots to determine the effect on Notch expression. 
Interestingly, of this panel only DGBP completely and dose-dependently decreased Notch1 
protein expression and levels of the Notch1 NICD in Molt-4 cells (Figure 12C), although a slight 
reduction was observed following treatment with 10 µM of lovastatin. Increasing concentrations 
of DGBP also increased the amount of the unprocessed non-geranylgeranylated Rab7 GTPase as 
indicated by a slight upward shift in the apparent molecular weight (Figure 12C). These results 
were consistent in Jurkat cells (Figure 12D), though a slight decrease in NICD also was observed 
following treatment with 100 µM of zoledronate. Both cell lines were expected to be resistant to 
γ-secretase inhibition, and indeed no inhibitory effect was observed on the Notch1 NICD at 
concentrations up to 100 μM of DAPT in either cell line. But surprisingly, the addition of DAPT 
increased the levels of NICD, especially in the Jurkat cells. Taken together, inhibition of GGDPS 
by DGBP uniquely decreases Notch1 expression, prevents Rab processing, and impairs cell 
viability. 
Notch depletion and cellular apoptosis induced by GGDPS inhibition are restored by γ-secretase 
inhibition 
We had previously determined that co-incubation with the GGDPS product GGPP 
(immediate rescue) or the pan-caspase inhibitor Z-VAD-FMK (downstream rescue) could 
abrogate the effects of GGDPS inhibition on cell viability (Agabiti et al., 2017). Here we asked 
whether or not these two rescue agents would affect the ability of DGBP to decrease Notch 
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expression. Co-incubation of DGBP with GGPP abrogated the ability of DGBP to reduce Notch 
expression (Figure 13A). In contrast, co-incubation with Z-VAD-FMK did not impact the ability 
of DGBP to decrease NICD expression (Figure 13B), indicating that the impact of GGDPS 
inhibition on Notch expression is not a generalized nonspecific phenomenon downstream of 
caspase activation. In contrast, DGBP increased cleaved Notch4 and increased expression of the 
ectodomain shedding protease tumor necrosis factor-α-converting enzyme (TACE), an effect that 
also was dependent on GGPP (Supplementary Figure S6). 
To determine whether or not GGDPS depletes Notch1 expression upstream or 
downstream of γ-secretase cleavage, we co-treated cells with the γ-secretase inhibitor (DAPT) in 
combination with DGBP. DAPT restored protein levels of Notch1 with DGBP co-incubation in 
both Molt4 (Figure 13C) and Jurkat cells (Figure 13D).  Furthermore, both DAPT and a second 
γ-secretase inhibitor MK-0752 dose-dependently reduced the effect of DGBP on cell viability 
(Supplementary Figure S5). The effect of both γ-secretase inhibitors was more pronounced when 
cells were assessed for apoptosis using Annexin V staining (Figure 13E/F). Therefore, DGBP 
reduces Notch expression in a way that is dependent upon GGPP depletion and γ-secretase 
activity, but independent of caspase activation, and like GGPP and caspase inhibition, γ-
secretase inhibitors reduce the effect of GGDPS inhibition on cell viability and apoptosis. 
GGDPS inhibition decreases c-myc expression 
We next sought to understand how reduced Notch expression caused by GGDPS 
inhibition would impact Notch signaling. Notch1 signaling affects transcription of a variety of 
genes, notably including c-myc (MYC), which promotes oncogenesis in T-cell leukemia 
(Sanchez-Martin and Ferrando, 2017, Weng et al., 2006). We treated Jurkat cells with DGBP and 
co-treated with GGPP or Z-VAD-FMK. GGDPS inhibition decreased levels of c-myc protein 
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expression, and co-treatment with GGPP restored the levels of c-myc (Figure 13G). Co-treatment 
with Z-VAD-FMK did not rescue the effect of DGBP on c-myc (Figure 13G), consistent with the 
pattern of activity that was observed with Notch1 expression. Co-treatment of DGBP with the 
proteasome inhibitor, MG132, did not rescue the effect of DGBP on c-myc depletion, consistent 
with transcriptional regulation of c-myc downstream of Notch1 rather than increased c-myc 
protein degradation (Figure 13G). Therefore, GGDPS-mediated Notch1 depletion reduces 
transcription of c-myc that is dependent on GGPP levels and is upstream or independent of 
cleaved caspases. 
GGDPS inhibition increases the DNA damage response mediated by ATM 
As c-myc transcription may not be the only underlying mechanism, we turned our 
attention to other consequences of Notch signaling. A recent report had demonstrated that Notch 
directly negatively regulates the DNA damage response (Vermezovic et al., 2015). The DNA 
damage response in Jurkat cells treated with DGBP is higher than that of primary T-cells treated 
with DGBP as demonstrated by phosphorylated histone H2A.X (Figure 14A). Because a well-
constructed study by Vermezovic et al. found that Notch1 binds to the kinase regulatory domain 
of ataxia telangiectasia mutated (ATM), and prevents ATM activation (Vermezovic et al., 2015), 
we set out to determine if GGPP depletion regulates Notch1 to induce ATM activation and the 
DNA-damage response. We tested whether ATM was required for the apoptotic effects of 
GGDPS inhibition.  Treatment of Molt-4 and Jurkat cells with Ku55933 (an ATM inhibitor) in 
combination with DGBP reduced the apoptosis induced by DGBP (Figure 14B). Therefore, 




c-abl mediates apoptosis induced by GGDPS inhibition in T-ALL 
Because c-abl (ABL-1) is activated by ATM for DNA damage-induced apoptosis (Matt 
and Hofmann, 2016), we predicted that GGDPS inhibition would activate c-abl. To determine 
the role of c-abl in apoptosis induced by GGDPS inhibition, we co-treated cells with DGBP and 
the c-abl inhibitor imatinib and determined the degree of apoptosis by Annexin V staining. 
Interestingly, DGBP-induced apoptosis was blocked by imatinib (Figure 14C). An additional c-
abl inhibitor, nilotinib, also reduced the apoptotic effect of DGBP in both the Molt-4 and Jurkat 
cells (Supplementary Figure S7). We knocked down c-abl expression using siRNA and treated 
cells with DGBP. Cells depleted of c-abl showed similar apoptosis with DGBP exposure as both 
non-transfected and scrambled cells exposed to DGBP (Figure 14D). Importantly, co-treatment 
with imatinib did not affect the ability of GGDPS inhibition to reduce Notch expression 
(Supplementary Figure S8), while co-treatment with DAPT did restore the effect of GGDPS 
inhibition on c-abl expression (Supplementary Figure S8), confirming that c-abl functions 
downstream of Notch in this system. 
To determine how GGDPS inhibition affects c-abl protein expression, we treated Jurkat 
cells with DGBP and either GGPP, Z-VAD-FMK, or imatinib (Figure 15). DGBP treatment 
decreased the 120 kDa fraction of c-abl and increased expression of the active 60 kDa cleavage 
product of c-abl (Figure 16A-C). The effect on c-abl was rescued by co-treatment with GGPP 
(Figure 15A). Co-treatment with Z-VAD-FMK also reduced the effect of DGPB on c-abl 
expression, indicating that the effects on c-abl were dependent upon caspase activation (Figure 
15B). While c-abl activation is thought to be upstream of cleaved caspases in some 
circumstances, cleaved caspases have been previously shown to at times cleave c-abl (Barila et 
al., 2003). Co-treatment with imatinib also restored expression of the 120 kDa form of abl and 
partially reduced expression of the 60 kDa form (Figure 15C). The pattern was also observed 
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with retinoblastoma protein (RB1) expression (Figure 15). The effect of DGBP on cleaved 
caspase 9 was fully rescued by GGPP and Z-VAD-FMK, but only partially rescued by imatinib 
co-treatment. The effect of DGBP on p-H2A.X was also rescued by GGPP, but not by Z-VAD-
FMK or imatinib. Thus, DGBP allows for Jurkat cells to respond to DNA damage, leading to the 
phosphorylation of H2A.X, depletion of retinoblastoma protein, and stimulation of caspase-
mediated c-abl cleavage. 
c-abl is required for apoptosis induced by chemotherapy agents and DGBP 
As c-abl is at the crux of DNA-damage response, we investigated the role of c-abl and 
imatinib in other common chemotherapies including: doxorubicin, cytarabine (AraC), and 
bortezomib. Both doxorubicin and cytarabine are used clinically for T-ALL therapy while 
bortezomib is a common chemotherapy that does not directly induce DNA damage. Both 
imatinib and nilotinib reduced the effects of DGBP in Jurkat and Molt-4 cells but not in Loucy 
cells (Figure 16). Additionally, imatinib and nilotinib reduced the effect of AraC on viability in 
all three cell lines. Imatinib and nilotinib did not rescue the effect of doxorubicin in Jurkat or 
Molt4 cells, but did reduce the impact of doxorubicin in Loucy cells. For bortezomib, imatinib 
and nilotinib rescued the effect on viability only in the Molt-4 cells. Taken together, in all of the 
cell line/c-abl inhibitor combinations tested, imatinib and nilotinib often reduced the effects of 
the chemotherapy agent and never increased their potency, supporting a role for c-abl in 
promoting cell death caused by these cytotoxic agents. 
Secretase, ATM, and caspases, but not GGDPS or c-abl, control Notch mRNA degradation  
Notch1 mRNA expression is regulated by miR-200 interaction with the Notch 3’UTR, 
which can be analyzed with a luciferase reporter construct that contains the luciferase gene 
flanked by the Notch1 3’ UTR (Zhang et al., 2016). We assessed the ability of DGBP and its 
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viability rescue agents to affect the miR-200 mediated regulation of Notch1 mRNA degradation. 
Treatment with DGBP did not significantly alter Notch mRNA stability in this system (Figure 
17A). However, treatment with DAPT, Ku55933, and to a lesser extent Z-VAD-FMK, decreased 
degradation of luciferase mRNA via the Notch 3’ UTR leading to elevated luciferase activity. 
This data suggests that miR-200 not only regulates Notch, but also that miR-200 is itself 
regulated by ATM. No impact on luciferase expression was observed following treatment with 
imatinib. 
GGDPS inhibition decreases expression of Notch1 in other hematological cell lines 
To examine the relationship between GGDPS and the Notch-ATM-abl axis in patients, 
we analyzed publically available databases for these proteins. As expected, we observed that 
Notch mRNA expression is increased in T-ALL patients compared to bone marrow from healthy 
patients (Supplementary Figure S9) (Tang et al., 2017). Correlation was found between GGDPS 
and ATM normalized to Notch1 expression across different cancer populations (Supplementary 
Figure S9) (Tang et al., 2017). Also, Notch1 mutant cell lines displayed increased sensitivity to 
saracatinib, an abl kinase inhibitor, compared to wild-type cells, which further underscores the 
relationship between Notch1 and c-abl (Supplementary Figure S9) (Yang et al., 2013). 
Treatment with DGBP in various hematological cell lines revealed that DGBP reduces active 
Notch in cell lines expressing Notch (Figure 17B). In Loucy cells, there is reduced DGBP 
sensitivity (Figure 16), low Notch1 expression (Figure 6B), and no effect of DGBP on levels of 
active Notch (Figure 17B). RPMI-8226, HL-60, and K562 cells expressed active Notch1 which 
decreased with treatment of DGBP (Figure 17B). Daudi cells had no expression of Notch. 
Overall, even in non-T-ALL hematologic cell lines that express active Notch1, treatment with 




Notch proteins are critical to development and progression of cancers including T-ALL, 
but disruption of Notch activity in T-ALL has been difficult to achieve. In this study, we 
demonstrate that inhibition of the enzyme GGDPS reduces expression of Notch and disrupts 
signaling through a Notch-ATM-abl pathway. DGBP is more potent than both DAPT and the 
other isoprenoid biosynthesis inhibitors at decreasing cell viability and levels of active Notch1 
(Figure 12). These experiments provide evidence for conserved regulation of Notch by lipid 
synthesis, and disruption of this mechanism can impact Notch expression and viability of Notch 
dependent cells. 
Because γ-secretase has been proposed as an anti-Notch target, we evaluated 
combinations of secretase inhibitors and DGBP to look for potential synergies. We surprisingly 
found that DAPT reduces the ability of DGBP to promote apoptosis and reduce NICD levels 
(Figure 13). Since Notch1 binds to the long range enhancer region to allow for the transcription 
of c-myc, and c-myc contributes to the oncogenicity of T-ALL, we tested whether DGBP would 
decrease c-myc levels. We found that DGBP decreased levels of c-myc in a manner than was not 
proteasome dependent, suggesting that DGBP decreases myc in a transcriptional manner (Figure 
14). Because Notch1 also functions in ways that are non-transcriptional, we investigated the 
effect of Notch1 on DNA damage response and found that co-treatment with ATM and c-abl 
inhibitors rescued the effect of DGBP on apoptosis (Figure 14). Furthermore, DGBP activates 
ATM to induce DNA damage response which is upstream of cleaved caspase 9. Cleaved caspase 
9 is upstream of retinoblastoma depletion and cleaved c-abl (Figure 15). Abl inhibitors mitigate 
the anti-proliferative effects, not only of DGBP, but also of relevant chemotherapy agents 
(Figure 16). Finally, we see that Notch1 mRNA degradation is regulated by DAPT and Ku55933 
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(Figure 17). But we do find that DGBP regulates Notch1 mRNA levels, therefore it is likely that 
DGBP alters Notch1 transcription (Supplementary figure S10). Further experiments are required 
to understand how DAPT plays a role in DGBP-mediated Notch1 transcriptional decrease and 
whether or not Notch1 regulates its own transciption. Ultimately, our results show that DGBP 
modulates the Notch1 signaling pathway to both regulate transcription of myc and initiate the 
ATM-dependent DNA damage response pathway to induce apoptosis. 
Using GGDPS inhibitors to target Notch signaling may be a promising therapeutic 
strategy because small GTPases such as Rab are natively involved in Notch processing. While 
direct inhibitors of γ-secretase may prevent Notch signaling in some cases, certain mutations 
may confer insensitivity. While mutations in Molt-4 and Jurkat cells such as loss of PTEN are 
well known (Palomero et al., 2007), the finding that DAPT can reduce the impact of DGBP 
treatment is suggestive of the idea that it is not mutations in PTEN that confer lack of sensitivity 
but rather the binding conformation of the γ-secretase inhibitor to the γ-secretase complex. 
Because small GTPases such as Rab11, Rab7, Rab8, and Rap1 are involved in both normal and 
mutant Notch1 processing, disrupting small GTPase function via inhibition of GGDPS allows for 
Notch1 disruption even in the event of mutations to Notch1. 
 How then does GGDPS inhibition deplete active Notch while a γ-secretase inhibitor, 
DAPT, induces active Notch1 expression in Molt-4 and Jurkat cell lines? DAPT is a non-
transition state inhibitor of the γ-secretase complex suggesting that it does not bind to the active 
site of the γ-secretase complex protease presenilin-1, but rather to an allosteric site within 
presenilin-1 (Olsauskas-Kuprys et al., 2013). Because there are mutations along the 
transmembrane region of Notch1 (Forbes et al., 2017), the binding conformation of the mutated 
alpha-helix may be different from the wild-type. Binding of DAPT in these cases may allow for 
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allosteric modulation rather than inhibition of the catalytic domain. Interestingly, there is overlap 
between the reported binding site of DAPT on presenilin-1 (aa372-467) (Dumanchin et al., 1999) 
and the binding site of Rab11 on presenilin-1 (aa374-400) (Morohashi et al., 2006). Perhaps 
binding of DAPT mimics binding of Rab to enable secretase processing of Notch1- though 
further experiments would be needed to confirm this hypothesis. 
 There is strong evidence in favor of the idea of repurposing isoprenoid biosynthesis 
inhibitors such as lovastatin and zoledronate for anti-cancer applications because zoledronate is 
currently used in the clinic for metastatic bone disease and because we and others have found 
that these inhibitors lead to apoptosis (Carter and Botteman, 2012, Fournier et al., 2008). 
Originally developed for non-cancer applications, these widely prescribed drugs have generated 
much interest for their potential anti-cancer properties. For example, a very recent article showed 
that statins could sensitize leukemia cells to venetoclax, a BCL-2 inhibitor, in a way that is 
dependent upon GGPP depletion (Lee et al., 2018). Interestingly, we observed GGDPS inhibition 
to affect Notch more strongly than the related clinical agents lovastatin and zoledronate, which 
target HMG-CoA reductase and farnesyl diphosphate synthase respectively (Pandyra et al., 2014, 
Wiemer et al., 2011). One potential explanation for this phenomenon is that, unlike GGDPS, 
both HMG-CoA reductase and farnesyl diphosphate synthase are under transcriptional control 
through cholesterol levels (Pandyra et al., 2015), which can mitigate the effects of these agents 
(Dudakovic et al., 2011, Brown and Goldstein, 1997). Alternatively, there may be a difference in 
rates of compound uptake, such as endocytosis, depending on cell line. As zoledronate has a 
higher charge:mass ratio than DGBP, its cellular entry is more likely to require endocytosis 
(Thompson et al., 2006).  
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 Here, we show that DGBP targets Notch1 signaling with a two-fold effect: 1) 
decreased transcription of the c-myc oncogene, and 2) induction of the ATM mediated DNA 
damage response. C-myc is a well-known downstream target of Notch1 in T-ALL (Sanchez-
Martin and Ferrando, 2017, Sharma et al., 2006, Weng et al., 2006). Because NICD binds to 
ATM and prevents its activation, Notch is directly involved in DNA damage response 
(Vermezovic et al., 2015). DGBP treatment depletes the Notch internal domain, which may free 
ATM to become activated. Active ATM phosphorylates H2A.X, a marker for DNA damage 
(Matt and Hofmann, 2016). We propose that GGPP depletion does not directly increase DNA 
damage, but rather allows for cells to recognize the level of DNA damage upon release of ATM 
inhibition by Notch. ATM ultimately activates cleaved caspases and initiates apoptosis (Korwek 
et al., 2012). Caspases will cleave retinoblastoma protein, which sits on the catalytic domain of 
c-abl and prevents its activation (Wang et al., 2001). There is some precedence for Notch 
involvement in retinoblastoma protein degradation as a γ-secretase inhibitor, which decreases 
active Notch, regulates retinoblastoma to exit the cell-cycle (Rao et al., 2009). Furthermore, 
lovastatin and nitrogenous bisphosphonates have been shown regulate retinoblastoma protein via 
induction of hypophosphorylation (Reszka et al., 2001). This reduction in retinoblastoma levels 
allows for caspases to cleave c-abl (Barila et al., 2003, Machuy et al., 2004), thereby depleting 
the 120 kDa c-abl protein. Since siRNA to c-abl did not rescue the effect of DGBP and since 
cleaved caspases deplete the 120 kDa c-abl, we predict that the 120 kDa c-abl is important to 
maintaining cell viability. While c-abl may be important in caspase initiated apoptosis, c-abl 
depletion in and of itself does not affect apoptosis. Perhaps this indicates the requirement of 
other signaling components such as retinoblastoma cleavage for c-abl to exert its effect. 
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Ultimately, these data indicate the connection between disruption of geranylgeranylation and 
induction of apoptosis in T-ALL. 
While we have found that GGPP depletion regulates Notch1 expression and signaling, we 
found that GGPP depletion does not affect Notch1 mRNA degradation. miR-200 interacts with 
Notch signaling in cancer stem cells in breast cancer (Shimono et al., 2015) and pancreatic 
cancer (Xu et al., 2017). Interestingly, only DAPT and Ku55933 increase levels of Notch1 
mRNA degradation. We predict that both of these inhibitors act through ATM inhibition. 
Ku55933 directly inhibits ATM, while DAPT indirectly decreases ATM activation by increasing 
active Notch1 and its subsequent binding to and inhibition of ATM. If ATM inhibition regulates 
Notch mRNA degradation, then it is not surprising that DGBP does not increase levels of Notch 
mRNA degradation because DGBP allows for the activation of ATM. 
In summary, GGDPS inhibition provides an alternate means of depleting active Notch1 to 
activate DNA-damage induced apoptosis. The effect of GGDPS inhibition on Notch1 signaling 
can be restored by co-incubation with a γ-secretase inhibitor. GGPP depletion ultimately allows 
for the activation of ATM and the induction of DNA-damage induced apoptosis through cleaved 
caspases and cleaved c-abl. 
Materials and Methods 
Supplies and Materials 
The cell lines Jurkat, Daudi, and HL-60 were obtained from ATCC (Manassas, VA, 
USA) prior to 2012. Molt-4 cells were obtained from ATCC in 2012. K562 cells were obtained 
from Sigma Aldrich (Saint Louis, MO) in 2012. RPMI-8226 cells were obtained from Coriell 
Institute (Camden, NJ) in 2013.  U2OS cells were obtained from ATCC in 2014. Cells were 
cultured in media containing RPMI-1640, 10% FBS, and Pen/Strep. Loucy cells were obtained 
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from ATCC in 2017 and cultured in T-cell media (RPMI-1640, 10% FBS, 
penicillin/streptomycin, non-essential amino acids, sodium pyruvate, 0.0004% 2-
mercaptoethanol, 10 mM HEPES pH 7.5). Cells were grown for at least two weeks after thawing 
before experimental use, and replaced with a fresh early passage stock after no more than three 
months. GGPP, DAPT, and coelenterazine were obtained from Cayman Chemical (Ann Arbor, 
MI, USA). DGBP was a generous gift from Dr. David Wiemer at the University of Iowa, Iowa 
City, IA. Z-VAD-FMK was obtained from ApexBio (Houston, TX, USA). Imatinib, nilotinib, 
and Ku55933 were obtained from LC laboratories (Woburn, MA, USA). Bortezomib was from 
Fisher. FITC-conjugated annexin V was obtained from Biolegend and propidium iodide was 
obtained from Fisher. 
Retinoblastoma protein (C-2) and c-myc (C-33) antibodies came from Santa Cruz (Santa 
Cruz, CA, USA). Notch4 (A-12) and TACE (B-6) antibodies were obtained from Santa Cruz 
(Santa Cruz, CA, USA). Cleaved caspase 9 (Asp330) (D2D4) and p-H2A.X (S139) (20E3) 
antibodies were from Cell Signaling Technologies (Danvers, MA). β-actin (Poly 6221) and c-abl 
(8E9) antibodies were obtained from  Biolegend (San Diego, CA, USA). The antibody for the 
Notch1 internal domain (bTAN20) was purchased from the Developmental Studies Hybridoma 
Bank (deposited by Artavanis-Tsakonas (Zagouras et al., 1995)). The antibody for actin (JLA20) 
was obtained from the Developmental Studies Hybridoma Bank (deposited by Lin, J.J. (Lin, 
1981)). 
The siRNA for c-abl and a negative control were obtained from Sigma. pCIneoRL-
Notch1 3'UTR was purchased from Addgene (plasmid # 84595) (deposited by Yanan Yang 




Cells were seeded at 100,000 cells/mL and incubated for 72 hours. Cells were transferred 
to microcentrifuge tubes and centrifuged at 600 g for 3 minutes. After the supernatant was 
aspirated, cells were resuspended in  200 µL of binding buffer (10 mM HEPES, 150 mM NaCl, 1 
mM MgCl2, 5 mM KCl, and 1.8 mM CaCl2, pH 7.4) and transferred to polystyrene test tubes. 
Two microliters of PI solution was used for each condition, while three microliters of annexin V 
were used for each condition. Cells were mixed by vortexing and data was acquired using a BD 
Fortessa and analyzed by FlowJo. 
Cell Viability 
Jurkat, Molt-4, and Loucy cells in log growth were seeded at 100,000 cells/mL in 96 well 
plates in 100 μL and incubated for 72 hours in the presence of compounds and fresh media. 10 
μL of CellQuantiBlue reagent was added per well for 2 hours and scanned on a Victor5 Perkin 
Elmer (Waltham, MA, USA) plate reader (ex550/em600). 
Electroporation 
Jurkat cells were grown in RPMI + FBS media without antibiotics overnight and seeded 
at 10 x 106 cells/ mL. Cells were washed in RPMI and resuspended in RPMI media at 25 x 106 
cells in 0.4 mL for each condition. Cells were incubated with DNA for 10 minutes before 
electroporation with a BioRad Gene Pulser Xcell at 316 V and 500 μF. Cuvettes were tapped 12 
times and incubated at room temperature before adding to pre-warmed media. After 24 hours, 
cells were resuspended at 1x 105 and selection agent was added. 
Luciferase assay 
After electroporation, Jurkat cells were seeded at 1 x 105 in 24 well plates and treated 
with compounds. After 72 hours, cells were centrifuged at 600 x g for 3 minutes and washed 
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with PBS. Cells were lysed with Renilla lysis buffer (0.5x PBS, 0.025% NP-40, 1% EDTA 
(w/v), and freshly added 5 μM coelenterazine) and sonicated in a water bath and immediately 
read on Victor5 Perkin Elmer (Waltham, MA, USA) plate reader for counts per second. BCA 
assay was carried out to determine total protein concentration (Pierce). 
Whole Cell Lysis 
Cells were seeded at 250,000 cells/mL and incubated for 72 hours. Cells were transferred 
to conical tubes for centrifugation at 600 x g for 3 minutes. Cells were washed with PBS and 
lysed with Whole Cell Lysis buffer (50 mM Tris pH 8.0, 2% SDS, 150 mM NaCl) then sonicated 
in a water bath. Lysates were then heated at 95°C on heating block and passed through 27 ½ 
gauge syringe. Protein quantification was determined using a BCA assay (Pierce). 
Western Blotting Analysis 
Western blotting was performed as previously described. Briefly, cells were resuspended 
in media at 250,000 cells/mL for 72 hours with test compounds or solvent controls. Cells were 
then washed with PBS and lysed in RIPA buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% 
NP-40, 1% sodium deoxycholate, 0.1% SDS) or Lysis buffer without SDS (25 mM Tris-HCl pH 
7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate) either containing freshly added 
protease and phosphatase inhibitors including aprotinin (1 μg/mL), leupeptin (1 μg/mL), 
pepstatin (1 μg/mL), PMSF (200 μM), sodium vanadate (200 μM), sodium diphosphate (10 μM), 
sodium fluoride (50 μM), and glycerophosphoric acid (10 μM). Cells were lysed for 10 minutes 
on ice and centrifuged for 10 minutes at 4°C at 14,000 x g. The supernatant was taken out and 
quantified by BCA assay (Pierce, Waltham, MA, USA). 1X SDS was added to the sample and 
the sample was then heated for 4 min at 95°C with vortexing. Equivalent masses were loaded 
onto 7.5% or 12% bis-acrylamide gels depending on protein size. Proteins were transferred to 
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nitrocellulose membranes, blocked with BSA, and blotted with primary antibodies. Alexa-Fluor 
680 goat-anti-mouse IgG and IRDye 800CW goat-anti-rabbit IgG were used as secondary 
antibodies. 
Gene Database Correlation and Drug Sensitivity Analysis 
The multiple gene correlation analysis for ATM and GGPS1 was obtained from the Gene 
Expression profiling Interactive Analysis (GEPIA) online database (http://gepia.cancer-pku.cn/) 
(Tang et al., 2017).  ATM and GGPS1 expression were normalized to NOTCH1 expression. The 
data for these primary tumor samples and normal samples were acquired from The Cancer 
Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) data sets. The drug 
sensitivity data was derived from the Genomics of Drug Sensitivity in Cancer Project 
(https://www.cancerrxgene.org/) (Yang et al., 2013). 
Real time RT Polymerase Chain reaction (RT-PCR) 
Cells were seeded at 100,000 cells/ mL in 5 mL. Cells were incubated with appropriate 
compounds for 72 hours. Total RNA was isolated with the TRIZOL (Invitrogen) according to the 
manufacturer’s protocol. The forward primer for Notch1 was: 5’AAT GCC TGC CTC ACC 
AA3’. The reverse primer for Notch1 was: 5’ CCA CAC TCG TTG ACA TCC T3’. The forward 
primer for 18S was: 5’ TAA GTC CCT GCC CTT TGT AAC ACA 3’. The 18S reverse primer 
was: 5’ GAT CCG AGG GCC TCA CTA AC 3’. RNA levels were determined with Nanodrop 
and cDNA was made using MMLV reverse transcriptase according to the manufacturer’s 
protocol. SYBR green protocol was used according to the manufacturer’s protocol on a 7500 




One-way ANOVA was used to determine statistical significance. Control conditions were 
compared to treatment conditions or between pairs of conditions indicated in the graphs. An α of 
0.05 was used to establish significance. Bar and line graphs represent mean ± SD. Experiments 




Figure 12. DGBP impacts Rab7 processing, decreases NICD protein levels and 
decreases cell viability.  
A-B) Cell viability of Molt-4 (A) and Jurkat (B) cells after 72 hours treatment with DAPT, 
lovastatin, zoledronate, or DGBP. Graphs display means and standard deviations of three 
independent experiments for each compound and cell line. C-D) Western blots for Rab7 and 
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NICD after 72 hours treatment with various concentrations of the γ-secretase inhibitor DAPT 
(GSI), the HMG-CoA reductase inhibitor lovastatin (Lov), the farnesyl diphosphate synthase 
inhibitor zoledronate (Zol), and the geranylgeranyl diphosphate synthase inhibitor DGBP (DG) 
in Molt-4 (C) and Jurkat cells (D). Tubulin is shown as a loading control. Blots are representative 







Figure 13. Secretase inhibitors rescue the effect of DGBP on NICD expression and 
apoptosis.  
A-B) Western blot of full-length Notch1 and NICD in Molt-4 cells following 72 hour treatment 
with DGBP and co-treatment with or without either the GGDPS product GGPP (A) or the 
caspase inhibitor Z-VAD-FMK (B). Tubulin is shown as a loading control. C-D) Western blots 
of Notch1 and NICD after 72 hour treatment with DGBP and co-treatment with or without 
DAPT in Molt-4 (C) and Jurkat (D) cells. E-F) Annexin V staining of Molt-4 or Jurkat cells 
treated with DGBP and co-treated with or without (E) DAPT or (F) MK-0752 for 72 hours. G) 
Western blots showing c-myc with DGBP treatment and co-treatment of GGPP, Z-VAD-FMK, 
and MG1332. Actin is shown as a loading control. All Western blots are representative of three 
independent experiments. Graphs represent means and standard deviations of 3 independent 
experiments. Statistical significance was determined by ANOVA. *p < 0.05 versus untreated 





Figure 14. DGBP-induced apoptosis is mediated by ATM and c-abl downstream of 
Notch.  
A) Western blot analysis of phosphorylated H2A.X in either expanded primary T-cells or Jurkat 
cells after 72 hours of treatment with DGBP, with actin shown as a loading control. B) Annexin 
V staining showing 72 hour DGBP treatment along with co-treatment with or without the ATM 
inhibitor Ku55955 in Molt-4 and Jurkat cells. C) Molt-4 or Jurkat cells were treated with DGBP 
with or without imatinib for 72 hours and assessed by Annexin V staining. Flow plots shown are 
representative of three independent experiments. D) Western blot of c-abl with electroporated 
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control with no DNA, scrambled siRNA and siRNA to c-abl. Annexin V staining for cells with 
electroporated without DNA, scrambled siRNA, and c-abl siRNA treated with imatinib, DGBP, 
or co-treatment with imatinib and DGBP. The bars represent means and standard deviations of 
three independent experiments (n=3).  *p < 0.05 versus untreated controls. ‡p < 0.05 versus 





Figure 15. DGBP induces activation of caspases, which cleave retinoblastoma and c-
abl.  
A) Western blotting analysis of p-H2A.X, cleaved caspase 9, retinoblastoma, and c-abl. Tubulin 
and actin are shown as loading controls. Molt-4 cells were treated for 72 hours with DGBP in the 
presence or absence of GGPP, Z-VAD-FMK, or imatinib. Western blots are representative of 







Figure 16. Inhibitors of c-abl are protective against apoptosis induce by 
chemotherapy agents.  
Dose response of Molt-4, Jurkat, and Loucy cell viability with DGBP, cytarabine (AraC), 
doxorubicin, and bortezomib, and in combination with either 10 µM imatinib or 10 µM nilotinib 







Figure 17. DGBP does not regulate mRNA degradation of Notch, but does regulate 
levels of active Notch in multiple hematological cell lines.  
A) Luciferase activity in Jurkat cells transfected with Notch 3’UTR. Cells were treated with 
inhibitor alone or co-treated with DGBP for 72 hours. B) Western blot of active Notch (NICD) in 
Loucy, Daudi, HL-60, K562, and RPMI-8226 cell lines. All Western blots are representative of 
three independent experiments. In all graphs the bars represent means and standard deviations of 





Supplementary figure S5. 







Supplementary figure S6. Notch signaling in T-ALL cell lines.  
A-C) Western blots of Notch4 and TACE with DAPT, DGBP, and GGPP co-treatment in Molt-4 
(A), Jurkat (B), and Loucy (C) cell lines. Cells were incubated for 72 hours then lysed for 
analysis. D-E) Cell viability of Molt-4 and Jurkat cells treated with γ-secretase inhibitor alone 
and with DGBP. D) Viability of cells with DAPT. E) Viability of cells with MK-0752. * denotes 
significant difference with respect to control, p <0.05. ‡ represents p<0.05 significant different 






Supplementary figure S7. C-abl inhibition has varying effects on cell viability.  
A) Annexin V/ PI staining of Jurkat and  Molt-4 cells treated with DGBP and with nilotinib. B) 
Quantification of nilotinib rescues. C) Cell viability of Jurkat cells treated with DGBP and co-
treated with dasatinib. D) Western blot of c-abl with Jurkat cells electroporated with media 
control (0), scrambled siRNA (scr), and c-abl siRNA (abl) and treated with solvent control and 
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DGBP. * denotes significant difference with respect to control, p <0.05. ‡ represents p<0.05 






Supplementary figure S8. C-abl is dose dependently decreased by DGBP and is downstream of 
Notch signaling. 
 A) Western blot of c-abl and increasing concentration of DGBP in Jurkat cells. B) Western blot 







Supplementary figure S9. Notch expression is implicated in multiple cancer cell types.  
A) Relationship between GGPS1 and ATM are correlated when compared to overall Notch1 
levels across many cancer types and patient samples (BRCA, CESC, DLBC, GBM, HNSC, 
LAML, LUAD, OV, PAAD, PRAD, ULEC, UCS). B) Notch mRNA levels in normal patient 
bone marrow and in T-ALL patients. C) Sensitivity of Notch1 mutant cell lines and Notch1 wild-






Supplementary figure S10. DGBP decreases Notch1 mRNA levels. 
A) Relative mRNA levels of Notch1 with varying concentrations of DGBP. Molt-4 cells were 




CHAPTER4. GERANYLGERANYL DIPHOSPHATE SYNTHASE 
INHIBITION AFFECTS THE HIPPO PATHWAY. 
 
Abstract 
Cell growth and proliferation are regulated in part by geranylgeranylated small GTPases. 
As such, multiple signaling pathways be involved. Many cancers have genes mutated that play a 
role in cell development. One such pathway that may be dysregulated in T-ALL is the Hippo 
pathway. Because isoprenoid biosynthesis pathway inhibitors decrease activation of the Hippo 
pathway protein YAP, we predicted that DGBP will affect the activity of YAP. Here, we show 
that GGDPS inhibition affects Hippo pathway effector YAP activation and Hippo pathway 
mediator protein expression levels. DGBP dose-dependently decreases phosphorylation of YAP 
at Ser127, and decreases expression of LATS1 and MOB1. While still preliminary, we have seen 
cells transfected with mutant YAP is more resistant to DGBP compared to those transfected with 
WT-YAP. Lastly, DGBP affects YAP and BCR-ABL in Philadelphia chromosome positive 
K562 cells.  
Introduction 
Yap1 (Yes-associated protein-1), a member of the Hippo pathway, is a transcriptional co-
activator involved in organ size control. Mouse models of inducible KRas indicated that in the 
absence of oncogenic KRas, the expression of Yap1 led to sustained tumors (Kapoor et al., 
2014). In tumors of epithelial origin, Yap1 is highly expressed and is often oncogenic. In 
hematological cancers, however, Yap1 is downregulated or deleted altogether (Cottini et al., 
2014). Many hematological cancers demonstrate a high level of DNA damage, but no apoptosis. 
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In down regulating Yap1, hematological cancers evade normal DNA damage response 
mechanisms leading to apoptosis. 
 YAP has been shown in the literature to be regulated by the isoprenoid biosynthesis 
pathway on multiple accounts. For example, Sorrentino et al demonstrated that zoledronate and a 
geranylgeranyl transferase inhibitor could prevent nuclear translocation of YAP/TAZ and 
mevalonate could not rescue this effect. But GGPP could rescue the presence of nuclear 
YAP/TAZ in cerivastatin-treated cells (Sorrentino et al., 2014). Moreover, constitutively active 
YAP transfected cells treated with increasing concentrations of cerivastatin were resistant to 
decreases in viability seen in the control (Sorrentino et al., 2014). Combination of an EGFR 
inhibitor and simvastatin reduced viability and YAP signaling while GGPP co-treatment restored 
viability and YAP activity (Liu et al., 2018). Finally, cerivastatin decreased p53 mediated 
transcription of cell cycle genes CCNB2 and CDK1 in a YAP-dependent manner (Di Agostino et 
al., 2016). Overall, these data suggest the link between YAP and geranylgeranyl diphosphate in 
controlling cell viability and provide a rationale for investigating the effects of DGBP on the 
Hippo pathway.  
We have previously seen that GGPP depletion alters the function of RhoA and Rac 
wherein DGBP increases the cytosolic levels of RhoA and Rac. Notably, DGBP also decrease 
the membrane levels of Rac. As geranylgeranylated proteins have been found to affect Raf-1, 
also known as c-Raf, we suspect there is a connection between Raf-1 and the anti-proliferative 
phenotype seen with administration of DGBP. We have also previously seen that a MEK 
inhibitor partially rescues the apoptosis induced by DGBP. This indicates that downstream of 
Raf-1 there is an effector that is partially involved in DGBP-induced apoptosis. But what else is 
responsible for DGBP-induced apoptosis? According to O’Neill et al, Raf-1 also modulates 
100 
 
MST2, a component of the Hippo pathway, by inhibiting MST2 activation (O'Neill et al., 2004). 
Therefore, we predict a pathway in which GGDPS inhibition leads to MST1/2 inactivation, 
preventing LAT1/2 phosphorylation and thereby decreasing phospho-YAP at Ser127 (Figure 
18). This would then allow for c-abl to phosphorylate YAP at Tyr357 and for YAP to translocate 
to the nucleus and bind to transcription factor p73 and c-abl to transcribe pro-apoptotic genes 
(Figure 18).  
Results and Discussion 
 To begin assessing the effect of a GGDPS inhibitor on the Hippo pathway, we first asked 
whether DGBP affects the phosphorylation of one of the Hippo pathway’s downstream effectors, 
Yes-associated protein (YAP). We treated Molt-4 and Jurkat cells with increasing concentrations 
of DGBP and found that DGBP dose-dependently decreased levels of phospho-YAP at Ser127 in 
both cell lines (Figure 19). Co-treatment of DGBP with GGPP also restored the effect of DGBP 
on levels of phospho-YAP Ser127 indicating that the effect shown on YAP is dependent on 
GGPP levels (Figure 19). When YAP is phosphorylated at Ser127 it is sequestered in the cytosol 
and is not transcriptionally active (Zhao et al., 2007). We show here that DGBP decreases levels 
of phosphor-YAP at Ser127, which can be rescued by addback of GGPP, suggesting that DGBP 
decreases levels of cytosolic YAP. YAP that is not phosphorylated at Ser127 is available to be 
phosphorylated by c-abl at Tyr537 and can translocate to the nucleus (Levy et al., 2008).  
 To further investigate this hypothesis that DGBP decreases levels of phosphorylated YAP 
at Ser127 and allows for the phosphorylation at Tyr357, we electroporated Jurkat cells with wild-
type YAP and YAP-Y357F (Figure 20). The YAP-Y357F mutant cannot be phosphorylated by 
c-abl and thus cannot translocate to the nucleus. We hypothesized that cells electroporated with 
YAP-Y357F would be more resistant to the apoptotic effects of DGBP than cells electroporated 
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with WT-YAP. Notably, the process of electroporation had a harmful effect on the cells as the 
no-DNA electroporated control demonstrated high basal levels of apoptosis. Also, the empty 
vector control was toxic towards the cells as untreated controls had a high percentage of 
apoptosis (40%). But both no-DNA electroporated control and empty vector control showed little 
change with GGPP, increased in apoptosis with DGBP, which was then restored back to basal 
levels with GGPP addback. Interestingly, WT-YAP had an even higher level of basal apoptosis 
that did not change with any of the conditions. DGBP did not increase apoptosis of WT-YAP 
electroporated cells. YAP-Y357F had basal levels of apoptosis similar to that of the empty 
vector. These levels increased with GGPP alone but did not increase with the addition of DGBP. 
Compared to WT-YAP treated with DGBP, YAP-Y357F treated with DGBP had lower levels of 
apoptosis. While this data partially supports the hypothesis, the data is still preliminary and the 
unchanging levels of apoptosis in WT-YAP have yet to be explained. 
 YAP and TAZ (WW domain containing transcription regulator 1) are both transcriptional 
coactivators, have similar functions, and are considered redundant (Plouffe et al., 2018). 
Therefore, in addition to testing a YAP mutant, we also tested a TAZ mutant (Figure 20). In 
contrast to WT-YAP, WT-TAZ had apoptosis levels similar to that of vector control. 
Furthermore, treatment with DGBP increased WT-TAZ apoptotic cells. The corresponding 
phosphorylation site for TAZ to enter the nucleus is Ser89 (Piccolo et al., 2014). Interestingly, 
the TAZ-S89A mutant apoptosis levels did not change with treatment conditions. One potential 
experiment to further investigate this is to separate the nuclear and cytoplasmic fractions and blot 
for the different tags incorporated into each construct. Overall, the mutant and wild-type 
electroporated cells had different effects and these effects were opposite for YAP and TAZ. This 
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suggests that YAP and TAZ may have separate functions in Jurkat cells or that these mutants 
may function differently.  
 To further assess the role of GGDPS inhibition on the Hippo pathway, we blotted for 
proteins in within the pathway (Figure 21). We treated Jurkat cells with solvent control, with 
GGPP alone, with DGBP alone, and with DGBP and GGPP. LATS1, which is responsible for 
phosphorylating YAP at Ser127, decreases in expression with administration of DGBP. Addback 
of GGPP restored levels of LATS1. Interestingly, overall levels of YAP decreased with 
treatment of DGBP, which may be why DGBP decreased levels of phospho-YAP Ser127. But 
addback of GGPP only partially restored levels of total YAP. MOB1 is involved in stabilizing 
MST1/2 to allow MST1/2 to phosphorylate LATS1/2 (Meng et al., 2016). DGBP treatment 
decreased protein expression of MOB1 which was rescued with addback of GGPP. Most 
interestingly, however, DGBP led to a band at 60 kDa for c-abl. This band, as further 
investigated in Chapter 3, is still c-abl. C-abl has been shown to be involved in Hippo pathway 
mediated apoptosis (Cottini et al., 2014). Whether or not c-abl is involved via p53 or p73, 
remains to be elucidated.  
  As shown in Chapter 3, c-abl inhibitors such as imatinib can prevent apoptosis induced 
by DGBP. But this is not how c-abl inhibitors are typically used in the clinic as their original 
intention was to inhibit BCR-ABL activity. BCR-ABL is a fusion oncoprotein resulting from the 
reciprocal translocation of chromosome 9 and 22 making BCR-ABL a tyrosine kinase that is 
constitutively active (Rowley, 1973, Hantschel, 2012). BCR-ABL is the hallmark of chronic 
myelogenous leukemia and plays an important role in its malignancy (Lugo et al., 1990, 
Deininger et al., 2000). Here we investigate how DGBP affects phospho-Yap Ser127 in a chronic 
myelogenous leukemia cell line K562 that expresses BCR-ABL. DGBP decreases levels of 
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phospho-YAP dose dependently (Figure 22). Lovastatin at 30 μM had a more pronounced 
decrease than DGBP at 30 μM. Dasatinib also decreased levels of phospho-YAP at 1 nM. This is 
interesting because dasatinib prevents activation of c-abl and would prevent activation of 
phospho-YAP at Tyr357. The fact that dasatinib has this effect indicates that BCR-ABL may 
also regulate levels of phospho-YAP Ser127. Thus, we also assess whether c-abl inhibitors could 
rescue the apoptotic effect of DGBP in the BCR-ABL mutant context. We found that imatinib 
rescued the effect of DGBP while nilotinib co-incubation increased apoptosis. Furthermore, the 
K562 cells were very sensitive to dasatinib, even though proliferation data showed that cells 
were still viable at 0.2 nM (Figure). The combination of dasatinib and DGBP lead to an even 
greater increase in apoptosis. This suggests that the effect of c-abl inhibitors on cancer cell 
viability is a structural matter, or that inhibition of off-target kinases such as Src by dasatinib 
may complicate interpretation. Interestingly, in the BCR-ABL context, imatinib and nilotinib 
have opposite effects suggesting that the rescue effect may be dependent on binding 
conformation.  
Materials and Methods 
Molt-4, Jurkat, and K562 cells were obtained from ATCC (Manassas, VA, USA). Cells 
were cultured in 10% FBS serum with penicillin and streptomycin. GGPP and XMU-MP-1 were 
obtained from Cayman Chemical (Ann Arbor, MI, USA). Imatinib, nilotinib and dasatinib were 
obtained from LC laboratories (Woburn, MA, USA). LATS1 (C66B5), MOB1 (E1N90), 
phosphor-YAP Ser127 (D9W21), and YAP/TAZ (D24E4) were obtained from Cell Signaling 
Technologies (Danvers, MA, USA). HA-TAZ (Addgene plasmid # 32839) and HA-TAZ-S89A 
(Addgene plasmid # 32840) were gifts from Kunliang Guan (Lei et al., 2008). pcDNA Flag Yap1 
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(Addgene plasmid # 18881) and pcDNA Flag Yap1 Y357F (Addgene plasmid # 18882) were 
gifts from Yosef Shaul (Levy et al., 2008).  
Western blotting 
Cells were seeded at 100,000 cells/ mL and cultured with indicated compounds for 72 
hours. Cells were washed with PBS and lysed with 25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% 
NP-40, 1% sodium deoxycholate) either containing freshly added protease and phosphatase 
inhibitors including aprotinin (1 μg/mL), leupeptin (1 μg/mL), pepstatin (1 μg/mL), PMSF (200 
μM), sodium vanadate (200 μM), sodium diphosphate (10 μM), sodium fluoride (50 μM), and 
glycerophosphoric acid (10 μM) and incubated for 10 minutes of sonication in a water bath. 
Total protein levels were quantified by BCA Assay (Pierce) and equivalent masses were loaded 
onto 5% or 7.5% bis-acrylamide gels for separation. Proteins were transferred onto nitrocellulose 
membranes and blocked with 5% BSA. Antibodies against Hippo pathway proteins were 
incubated with 5% BSA overnight on rotator at 4 C. Blots were visualized using Licor Odyssey.  
Electroporation 
Jurkat cells were allowed to grow overnight in antibiotic-free media. Cells were washed 
once with RPMI-1640 and resuspended at 25 x 106 cells/ mL. 0.4 mL of cells was added to 20 μg 
of DNA in electroporation cuvettes. This mixture was incubated for 10 minutes at room 
temperature prior to electroporation. Electroporation was conducted on a Biorad GenePulser XL 
according to the exponential protocol at 316 V and 500 μF and allowed to rest at room 
temperature for 15 minutes before being transferred to 6 well plates. After 24 hours, cells were 




Cells were seeded at 100,000 cells/ mL. After 72 hour incubation with compounds, cells 
were washed with PBS and resuspended in 200 μL of 1x Binding Buffer (10 mM HEPES, 150 
mM NaCl, 1 mM MgCl2, 5 mM KCl, and 1.8 mM CaCl2, pH 7.4) then transferred to polystyrene 
flow tubes. 2.5 μL of FITC Annexin V (Biolegend) solution were added to the tubes. 2 μL of PI 
(Sigma-Aldrich, St. Louis, MO) 50 μg/mL solution were added to the tubes. Samples were 







Figure 18. Proposed pathway of how GGDPS inhibition affects the Hippo pathway 
to induce apoptosis in T-ALL. 
 
GGDPS biosynthesizes GGPP, which can be inhibited by DGBP. GGPP allows for small 
GTPases such as Rho and Rac to be membrane-associated. Inhibition of GGDPS depletes GGPP, 
which prevents these GTPases from being membrane-associated and allows them to interact with 
Raf-1, which then inhibits MST2 and activates MEK1/2 and ERK1/2. If MST2 is not inhibited 
by Raf-1, it associates with RASSF1A, which activates LATS1/2. LATS1/2 then phosphorylates 
YAP at Ser127 preventing it from translocating to the nucleus. If Raf-1 inhibits MST2, then 
LATS1/2 does not phosphorylate YAP at Ser127 allowing it to be phosphorylated by Abl-1 or c-
abl at Tyr357. This phosphorylation event allows YAP to translocate to the nucleus and bind to 





Figure 19. GGDPS inhibition decreases levels of phospho-YAP Ser127.  
A) Western blots showing phospho-YAP levels in Jurkat cells with dose response of DGBP (top) 
and addback of GGPP (bottom). B) Western blots showing phospho-YAP levels in Molt-4 cells 





Figure 20. YAP and TAZ transfected mutants have different responses to DGBP.  
A) Annexin V staining as determined by flow cytometry of Jurkat cells transfected with WT-
YAP and YAP-Y357F. B) Annexin V staining as determined by flow cytometry of Jurkat cells 





Figure 21. DGBP decreases expression of Hippo pathway proteins. 
A) Western blots of various Hippo pathway proteins in Jurkat cells treated with DGBP and co-
treated with GGPP. B) Western blots of c-abl or Abl-1 in Molt-4 cells. Cells were treated with 
DGBP for 72 hours. C) Annexin V/ PI staining as determined by flow cytometry of Jurkat and 
Molt-4 cells treated with XMU-MP-1 an MST1/2 inhibitor.  Cells were treated for 72 hours prior 




Figure 22. Isoprenoid biosynthesis pathway inhibitors and c-abl inhibitors in K562 
cells. 
A) Western blots of phospho-YAP Ser127 in K562 cells after treatment with varing 
concentrations of DGBP, lovastatin, and dasatinib. B) Raw Annexin V/ PI staining flow 
cytometry plots of DGBP-treated K562 cells and co-treatment with c-abl inhibitors: imatinib, 
nilotinib, and dasatinib. N=1 for Westerns and flow cytometry experiments shown in this figure. 
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CHAPTER 5: ASSESSING THE ROLE OF ISOPRENOID 
BIOSYNTHESIS PATHWAY INHIBITORS IN RPMI-8226 CELLS. 
 
Abstract 
DGBP affects multiple pathways that ultimately decrease cell viability and induce 
apoptosis. DGBP induces cleaved caspases, activates ERK, depletes levels of active Notch1, and 
activates ATM and other DNA damage-response pathway components in T-ALL cell lines.  But 
does GGDPS inhibition affect other pathways and how does it act in other cellular contexts 
compared to other isoprenoid biosynthesis pathway inhibitors? In this chapter, I explore the 
effects of DGBP in a different cellular context that differed from the T-ALL lines that we 
investigated previously. Here I examine the RPMI-8226 multiple myeloma cell line. RPMI-8226 
has been shown previously to respond to geranylgeranyl diphosphate synthase inhibitors (Zhou 
et al., 2014). In this chapter, we investigated the role of isoprenoid biosynthesis inhibitors on 
VEGF cytokine levels, Rab3A mRNA levels, and on Rab GTPase localization in RPMI-8226 
cells. Because isoprenoid biosynthesis pathway inhibitors have differential effects on sterol 
levels, we predicted that they would differentially effect Rab GTPase expression and levels of 
cytokine secretion. The results showed that lovastatin and DGBP differentially affected mRNA 
levels and VEGF levels, but they did not differently affect Rab5A and Rab9A expression or 
localization. 
Introduction 
The RPMI-8226 cell line provides a good model for study of geranylgeranyl diphosphate 
synthase inhibition for several reasons. RPMI-8226 cells are interesting because zoledronate, 
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another bisphosphonate, is already clinically approved for multiple myeloma. Another rationale 
for investigating the role of GGDPS inhibitors in RPMI-8226 is that RPMI-8226, unlike the T-
ALL lines explored here thus far, are KRas mutated (Ramakrishnan et al., 2012). This mutation 
allows for increased signaling through the Ras/MAPK signaling pathway. It has been thought 
that targeting Ras/MAPK will prevent proliferation of KRas mutant cells. Indeed, inhibition of 
ERK has been shown to induce senescence in KRas mutant pancreatic cancer (Hayes et al., 
2016). Due to the clinical relevance and KRas role, we proposed that using an inhibitor to 
farnesyl transferase in combination with DGBP would result in synergistic anti-proliferative 
activity. 
Multiple myeloma is partially driven by its microenvironment. The bone marrow 
microenvironment allows for the secretion of growth factors and initiates angiogenesis, 
ultimately supporting the growth of the tumor. Vascular endothelial growth factor (VEGF) is a 
cytokine responsible for initiating angiogenesis by stimulating endothelial sprouting and vascular 
permeability in nearby blood vessels (Rini, 2005). As most cytokines are subject to vesicular 
trafficking and Rab GTPases play an important role in vesicular trafficking, we hypothesized that 
GGDPS inhibition would decrease VEGF levels. Because the bone marrow microenvironment is 
important in T-ALL relapse as relapsed T-ALL bone is particularly resistant to standard 
treatment, it is important to investigate the cytokines involved in the bone marrow 
microenvironment. 
The isoprenoid biosynthesis pathway is partially regulated by sterol levels as cholesterol 
depletion and FPP depletion lead to increased transcription of isoprenoid biosynthesis enzymes 
such as HMG-CoA reductase via SREBPs. It has also been shown that statin treatment can affect 
levels of small GTPases. In this chapter, we determine how DGBP and lovastatin affect small 
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GTPase mRNA levels. We predict that because lovastatin controls sterol levels that this 
decreased sterol level will activate SREBPs and increase transcription of Rab GTPases. 
Results and Discussion 
We started this study by investigating the effects of multiple isoprenoid biosynthesis 
pathway inhibitors on RPMI-8226 cell viability. Interestingly, tipifarnib, an inhibitor of farnesyl 
transferase, was most potent of these compounds with an IC50 of 0.15 μM (Figure 23A-D). 
Lovastatin was next at 2.1 μM and DGBP had an IC50 of 8.0 μM. Zoledronate had the highest 
IC50 of these compounds (33 μM) despite being the only one approved for clinical anti-myeloma 
use. These data suggest that there is potential for the use of other isoprenoid biosynthesis 
inhibitors in multiple myeloma contexts. 
While the use of one of these inhibitors indicated promising effects, we hypothesized that 
the use of multiple inhibitors would be antagonistic if combined with zoledronate. We tested the 
combination of zoledronate with DGBP and zoledronate with tipifarnib. We also tested tipifarnib 
with DGBP. We predicted that the combination of DGBP with tipifarnib would be synergistic 
because the GGPP was not likely under SREBP control and inhibiting farnesylation would likely 
decrease Ras activity. Preventing the membrane association of both geranylgeranylated proteins 
and farnesylated proteins such as KRas will likely decrease viability of cells compared to 
preventing the membrane association of either group alone as both are involved in cell 
proliferation. The combination of tipifarnib and zoledronate are slightly antagonistic (Figure 
23E). Interestingly, DGBP and tipifarnib are only slightly synergistic (Figure 23F). The 
combination of DGBP and zoledronate are strongly antagonistic (Figure 23G), which was similar 
to what we demonstrated in Molt-4 cells. 
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In order to investigate how isoprenoid biosynthesis pathway inhibitors affect VEGF 
levels, we treated RPMI-8226 cells with lovastatin alone, lovastatin with GGPP, DGBP alone, 
and DGBP with GGPP and then measured levels of VEGF-A in the media. We predicted that 
both lovastatin and DGBP would decrease VEGF.  Lovastatin decreased levels of VEGF by 
approximately half while DGBP decreased VEGF levels minimally (Figure 24). Co-incubation 
of GGPP restored the effect of lovastatin. In contrast, co-incubation of GGPP with DGBP 
increased VEGF levels by two-fold compared to the control. Overall, we found that lovastatin 
decreased VEGF levels but DGBP did not. These results were surprising because DGBP had a 
minimal effect. We proposed that because GGDPS is closer in the isoprenoid biosynthesis 
pathway to Rab GTPases in comparison to HMG-CoA reductase that DGBP would be more 
potent in regulating Rab GTPases and therefore be more potent in regulating levels of VEGF. 
Interestingly, the fact that lovastatin could be rescued by addition of GGPP. Perhaps increased 
GGPP levels increase active geranylgeranylated GTPases and increase levels of VEGF. While 
the effects of lovastatin were interesting, we chose not to continue these assays as VEGF is 
primarily involved in paracrine functions and would best be investigated with a 
microenvironment model where other cell types are present (Dankbar et al., 2000). 
We hypothesized that isoprenoid biosynthesis pathway inhibitors may regulate the 
mRNA levels of GTPases. To test this, we treated cells with lovastatin alone, lovastatin with 
GGPP, DGBP along, and lovastatin with GGPP. We found that lovastatin treatment decreased 
Rab3A mRNA levels while DGBP increased Rab3A mRNA levels (Figure 25). Simultaneously, 
GGPP co-incubation with lovastatin partially rescued the effect of lovastatin. And addback of 
GGPP to DGBP-treated cells also restored the effect of DGBP. These data suggest that SREBPs 
are involved in regulating not only isoprenoid pathway enzyme levels but also in regulating 
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small GTPases. To further test this in the future, we would use a knock-down model of SREBPs 
and determine whether the same effect is seen with other small GTPases. We also investigated 
the protein levels of Rab3A and found that they were low compared to both tubulin and 
unprenylated Rap1a (Figure 25C). Unprenylated Rap1a was used as a positive control to 
determine whether or not lovastatin and DGBP were preventing prenylation. Because the protein 
levels of Rab3A are low (Figure 25B), the effects on mRNA levels may not have large 
consequences on overall cell signaling. Therefore, we chose to explore the effects of isoprenoid 
biosynthesis pathway inhibitors on Rab protein expression and membrane localization. 
 While Rab3A had low protein expression, other Rab GTPases were better expressed in 
the RPMI-8226 cells. We compare the effects of an untreated/solvent control, DGBP, 
risedronate, lovastatin, as well as a co-incubation condition with GGPP for each compound, on 
protein expression and membrane localization. Rab5A had low levels of expression, but 
demonstrated high membrane localization without treatment (Figure 26). Treatment with DGBP, 
risedronate and lovastatin all increased the cytosolic levels and decreased the membrane levels. 
Also, co-incubation with GGPP restored these levels. Rab9A had high levels of basal expression 
with high membrane levels. Rab9A was affected by the isoprenoid biosynthesis pathway 
inhibitors in the same fashion as Rab 5A. Most interestingly with Rab9A, the co-incubation with 
GGPP decreased the overall expression levels suggesting that elevated levels of GGPP may 
decrease Rab9A expression. Rab11A was also more cytosolic than membrane localized with 
DGBP treatment. In contrast to the other GTPases, however, Rab11A decreased in overall 
expression with DGBP treatment, which was partially rescued by addback of GGPP. Overall, 
these data suggest that these inhibitors act similarly on GTPase membrane localization, and the 
levels of GGPP may affect expression levels. One future experiment that could be done to further 
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explore this idea is determining the mRNA levels of Rab9A and Rab11A and treating with 
similar conditions along with GGPP alone at different concentrations. 
 
Materials and Methods 
RPMI-8226 cells were obtained from ATCC and grown according to ATCC’s recommendation 
in 10% FBS media. Rab 11 (D4F5), Rab9 (D52G8), and Rab5 (C8B1) were obtained from Cell 
Signaling (Danvers, MA, USA). Rab3A (K-15) and Rap1a (C-17) antibody was obtained from 
Santa Cruz Biotechnology (Santa Cruz, CA, USA). E7 tubulin was deposited to the DSHB by 
Michael Klymkowsky (DSHB Hybridoma Product E7) (Chu and Klymkowsky, 1989). The 
VEGF-A ELISA kit was obtained from Thermo Fisher (Waltham, MA, USA).   
Cell Viability 
Cells were cultured and seeded in fresh media at 100,000 cells/mL in 100 µL in 96 well plates. 
Cells were incubated with the appropriate compounds for 72 hours. 10 μL of CellQuantiblue 
reagent was added to each well and incubated at 37°C for 2 hours before reading on Victor V 
plate reader (Perkin Elmer). Combinatorial effects were calculated using Calcusyn Software 
(Biosoft, Cambridge, UK). Combination Index values were calculated according to the Chou and 
Talalay method (Chou and Talalay, 1984). Isobolograms were generated for combinations using 
80% dilutions of each compound based on their individual IC50 values.  
VEGF-A ELISA 
RPMI-8226 cells were seeded and cultured in 48-well plates for 48 hours. 96 well plates were 
coated with VEGF-A capturing antibody and blocked 24 hours before 48-hour time point. Media 
was transferred to microcentrifuge tubes and centrifuged for 3 minutes at 600 x g. Media was 
then added to coated plates and the manufacturer’s protocol was followed for VEGF-A standard 
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curve and the rest of the protocol. Absorbance at 450 nm and 550 nm were read on a Victor V 
plate reader (Perkin Elmer). 
Real time RT Polymerase Chain reaction (RT-PCR) 
Cells were seeded at 100,000 cells/ mL in 5 mL. Cells were incubated with appropriate 
compounds for 48 hours. Total RNA was isolated with the TRIZOL (Invitrogen) according to the 
manufacturer’s protocol. The forward primer for Rab3A was: 5’ATC AAG CTG CAG ATC 
TGG GAC ACA 3’. The reverse primer for Rab3A was: 5’ AAG AAC TCG AAC CCA AGG 
TGG TCA 3’. The forward primer for 18S was: 5’ TAA GTC CCT GCC CTT TGT AAC ACA 
3’. The 18S reverse primer was: 5’ GAT CCG AGG GCC TCA CTA AC 3’. RNA levels were 
determined with Nanodrop and cDNA was made using MMLV reverse transcriptase according to 
the manufacturer’s protocol. SYBR green protocol was used according to the manufacturer’s 
protocol on a 7500 Applied Biosystems PCR machine. Relative mRNA levels were determined 
by 2-ΔΔCt values.  
Triton X-114 phase separation and Western blot 
Membrane and cytosolic fractions were isolated using Triton X-114. Cells were resuspended at a 
concentration of 750,000 cells/mL and cultured for 48 hours. Cells were washed with PBS and 
resuspended in 4°C Triton X-114 lysis buffer (20 mM Tris pH 7.5, 150 mM NaCl, 1% Triton X-
114) with freshly added protease inhibitors. Lysate was passed through a 27 gauge ½ inch needle 
until homogenous and centrifuged for 15 minute at 12,000 x g at 4°C. 40 μL of this supernatant 
was reserved to determine whole cell lysate protein levels. The supernatant is transferred to a 
new microcentrifuge tube and incubated in a 37°C water bath for 10 minutes. The supernatant 
was then centrifuged at room temperature at 12,000 x g for 2 minutes. The resulting aqueous 
phase (upper) and detergent phase (lower) were then separated and diluted. A BCA assay was 
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used to determine total protein concentration. Western blot analysis was performed as described 







Figure 23. Isoprenoid biosynthesis pathway inhibitors decrease cell viability in 
RPMI-8226 cells. 
A) Dose response of lovastatin. B) Dose response of zoledronate. C) Dose response of DGBP. D) 
Dose response of tipifarnib. For A-D, n=3 mean ± SD. E) Isobologram of zoledronate and 
tipifarnib, n=1. F) Isobologram of DGBP and tipifarnib, n=1. G) Isobologram of DGBP and 
zoledronate, n=1. EC75 values were used to calculate isobologram data. Cells were incubated for 




Figure 24. Lovastatin decreases relative VEGF-A levels in RPMI-8226 cells.  
Relative VEGF-A levels of RPMI-8226 cell media as determined by ELISA. Left: Cells were 
treated with lovastatin and co-treatment with GGPP. Right: Cells were treated with DGBP and 




Figure 25. Isoprenoid biosynthesis pathway inhibitors affect the expression of 
Rab3A. 
A) Relative mRNA levels of Rab3A in RPMI-8226 cells with treatment of lovastatin and co-
treatment with GGPP. B) Relative mRNA levels of Rab3A in RPMI-8226 cells with treatment of 
DGBP and addback of GGPP. C) Western blot of Rab3A and Rap1A protein expression levels in 




Figure 26. Isoprenoid biosynthesis pathway inhibitors change the localization of 
Rab GTPases in RPMI-8226 cells.  
“W” represents whole cell lysate. “C” represents the cytosolic fraction. “M” represents the 
membrane fraction. A) Western blot of Rab5A, Rab9A, Rab11A showing whole cell, cytosolic, 
and membrane fractions separated using the TritonX-114 protocol. RPMI-8226 cell were treated 
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with DGBP and co-treated with GGPP. B) Western blot of Rab5A and Rab9A showing whole 
cell, cytosolic, and membrane fractions separated using the TritonX-114 protocol. RPMI-8226 
cell were treated with risedronate and co-treated with GGPP. C) Western blot of Rab5A and 
Rab9A showing whole cell, cytosolic, and membrane fractions separated using the TritonX-114 
protocol. RPMI-8226 cell were treated with lovastatin and co-treated with GGPP. N = 1 for the 
depicted experiments.  
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Chapter 6: Conclusions 
 
Introduction 
The isoprenoid biosynthesis pathway has a history of being a target for anti-cancer 
therapies (Dewick, 2002). Inhibitors for multiple enzymes have been targeted suggesting the 
importance of understanding this pathway and its downstream signaling effects (Figure 27).  
Nitrogenous bisphosphonates have been successfully used as inhibitors to farnesyl diphosphate 
synthase (FDPS) in osteoporosis to prevent bone resorption (Hamdy, 2010). Zoledronate, a 
bisphosphonate that inhibits FDPS, has been repurposed for multiple myeloma and is successful 
in the clinic (Terpos et al., 2013). Another group of isoprenoid biosynthesis pathway inhibitors 
that has been suggested for anti-cancer therapy is the statins. Statins have recently been 
implicated in decreasing proliferation of cell line models (Jiang et al., 2014). Interestingly, 
GGPP co-incubation can often rescue the effect of statins, and geranylgeranyl transferase 
inhibitors often recapitulate the effect of statins (Kotamraju et al., 2007, Gbelcova et al., 2017, 
Lee et al., 2018). Thus, the effect of statins and nitrogenous bisphosphonates is thought to be due 
to inhibition of prenylation, and in many cases, specific to geranylgeranylation. 
 The prenyltransferases are further downstream in the isoprenoid biosynthesis pathway 
and pharmaceutical efforts were poured into their preclinical development (Appels et al., 2005). 
Farnesyl transferases have been targeted mainly due to the established role of KRas as a cancer 
driver (Brunner et al., 2003). But these inhibitors were not shown to be clinically effective, in 
large part due to alternative geranylgeranylation of KRas under conditions of farnesyltransferase 
inhibition (Appels et al., 2005, Whyte et al., 1997). Geranylgeranyl transferase inhibitors are 
potentially good therapeutic agents because of their close proximity within the pathway to small 
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GTPases (Figure 27). But because there are two primary transferases and there may be some 
redundancy amongst the small GTPases, it is possible for other small GTPases to compensate for 
the inhibited GTPases. While it would be ideal to identify the small GTPase responsible for the 
maintaining viability, there are many geranylgeranylated small GTPases and a combination of 
them may be responsible since they thought to act as a class rather than as single entities 
(Hentschel et al., 2016, Mullen et al., 2016). Therefore, geranylgeranyl diphosphate synthase 
(GGDPS) is an attractive target because it is uniquely poised to prevent the membrane 
association of multiple small GTPases.   
Depletion of a metabolite or inhibition of a signaling pathway? 
While impaired prenylation is thought to be the source of the decrease in viability 
observed following isoprenoid depletion, the fact that GGPP rescues the viability may suggest 
that this may be due to depletion of a metabolite derived from GGPP. There are downstream 
metabolites that are made from GGPP such as menquinone-4 (Figure 27). UBIAD1 has been 
identified as a prenyltransferase that adds GGPP to the napthoquinone to form menaquinone-4, a 
vitamin K2 homolog (Nakagawa et al., 2010). UBIAD1 has been shown to be involved in non-
mitochondrial biosynthesis of ubiquinone (Mugoni et al., 2013). Whether or not this requires 
GGPP, however, is not known. But because UBIAD1 is involved in zebrafish (Mugoni et al., 
2013) and UBIAD1 has a GGPP binding site, it is possible for UBIAD1 to add GGPP to form 
co-enzyme Q10. Recently, Yu et al. used a variety of mutant and myrisytolated GTPases to show 
that the effect of statins could be uncoupled from prenylation (Yu et al., 2018). This prompted 
them to suggest that while the effects of statins could be rescued by GGPP co-incubation, that 
the effect of GGPP was due to depletion of a downstream metabolite such as dolichol or 
ubiquinone. While they tested substrates of GGTase I, they did not test substrates of GGTase II 
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nor did they evaluate a GGTase II inhibitor. Therefore, the effect of statins could still go through 
GGTase II modified small GTPases such as Rab. Nevertheless, it is important to investigate 
whether or not the effect of GGPP is due to downstream depletion of isoprenoid biosynthesis 
pathway metabolites. While it is possible that the effects of isoprenoid biosynthesis pathway 
inhibitors are due to depletion of metabolites downstream of GGPP, the fact that geranylgeranyl 
transferase inhibitors can recapitulate the effect of the statins (van de Donk et al., 2003), 
nitrogenous bisphosphonates (Wilke et al., 2014, Hasmim et al., 2007), and geranylgeranyl 
diphosphate synthase inhibitors (Dudakovic et al., 2011), suggests that this effect is due to 
geranylgeranylation and not depletion of a downstream metabolite. 
In addition to discussion of whether prenylation is responsible, there is also discussion of 
whether or not GGPP itself is necessary for maintaining viability. In chapter 2 we discuss that 
GGPP not FPP robustly rescues the decrease on viability of bisphosphonates DGBP and 
zoledronate. Furthermore, GGPP is a better rescue agent than FPP in bisphosphonate-mediated 
apoptosis in T-ALL. Yu et al. has also found that GGPP not FPP rescues the effect of statins in 
breast cancer cell lines. Despite these findings, Malwal et al. argues that because Mitrofan et al. 
(Mitrofan et al., 2009) found that zoledronate treatment and GGOH co-treatment resulted in very 
low levels of IPP, that GGOH also inhibits mevalonate kinase and prevents isoprenoid 
biosynthesis through IPP depletion (Hinson et al., 1997, Malwal et al., 2018). Henneman et al. 
noted that non-sterol isoprenoids can be detected using HPLC-MS/MS showing that inhibiting 
FDPS with pamidronate increases IPP/DMAPP (there is also a slight increase in GPP) in a time-
dependent manner, and leaving little to no GGPP or FPP (Henneman et al., 2008). Further 
studies are necessary to determine whether the effect of GGDPS inhibition and GGPP addback 
has any effect of levels of upstream metabolites. 
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GGPP also regulates the isoprenoid biosynthesis pathway upstream of GGDPS by aiding 
in the degradation of HMG-CoA reductase. Interestingly, insig-dependent and sterol-stimulated 
degradation of HMG-CoA reductase is augmented by GGOH, but not by FOH (Sever et al., 
2003). UBIAD1-mediated degradation of HMGCR is regulated by a geranylgeranylated protein 
as GGTI-298 prevents the ubiquitylation of HMGal, a chimeric protein containing the membrane 
region of HMGCR that is sufficient to drive endoplasmic-reticulum-associated degradation 
(Leichner et al., 2011). Further studies are necessary to determine whether GGPP-mediated 
degradation of HMG-CoA reductase regulates transcription of isoprenoid biosynthesis enzymes. 
New findings in geranylgeranyl diphosphate synthase inhibition 
GGDPS is gaining traction as a target for cancer. Recently, Lacbay et al. identified 
several new potent GGDPS inhibitors. These inhibitors are thienopyrimide-based 
bisphosphonates with EC50 toward RPMI-8226 cell proliferation less than 1 μM. Enzymatic 
inhibition with compound 10 and 11 analogs demonstrated IC50 values ranging from 42 nM to 
100 nM (Figure 28). Even more, Lacbay et al. found that 11c increased phosphorylation of 
ERK1/2 and decreased phosphorylated Akt, which corroborates our results shown in Chapter 2. 
Overall, this new type of GGDPS inhibitor showed IC50 values comparable to that of VSW1198 
described in Chapter 1, induced apoptosis across multiple cancer cell lines and decreased serum 
mouse immunoglobulin in a mouse multiple-myeloma model. Pre-clinical studies have also 
recently been performed for the E/Z mixture of VSW1198. VSW1198 was found in the bone 
marrow, brain, liver, spleen and kidney. VSW1198 prevented Rap1 geranylgeranylation in the 
liver, spleen and kidney. Interestingly, the Z-isomer was more prevalent in the bone marrow 
(Haney et al., 2018). In clinical models, overexpression of GGDPS in lung carcinoma patients 
correlated with decreased overall survival. But this effect is likely more related to migration and 
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metastasis than apoptosis as decreased GGDPS via siRNA decreased migration and invasion 
while addback of GGPP restored the effect of the GGDPS knock-down (Wang et al., 2018). In 
conclusion, there is increased interest in GGDPS as a target both in inhibitor development and in 
pre-clinical studies. 
DNA damage and geranylgeranylation 
Throughout chapters 2 and 3, we demonstrate that GGDPS inhibition activates DNA-damage 
response induced apoptosis (Figure 29). In Chapter 2, we discuss how DGBP increases 
phosphorylated ERK to increase apoptosis. Interestingly, the most prominent effects of activated 
ERK in apoptosis is shown in cisplatin-treated cells suggesting that ERK is involved in DNA-
damage response. Moreover, an ATM inhibitor could rescue the effects of etoposide on ERK 
activation. Thus, indicating the role of ERK in DNA damage response. In Chapter 3, we found 
that DGBP decreased active Notch1 levels and a Notch1 processing inhibitor could rescue the 
effects. Furthermore, an ATM inhibitor and c-abl inhibitors could rescue the apoptotic effect of 
DGBP. But this is not the first association of geranylgeranylation and DNA damage because Sun 
et al. found that GGTI-298 induced hypophosphorylation of RB1 in lung carcinoma cell line 
Calu-1 (Sun et al., 1999). More studies are required to understand how DNA damage response 
occurs in GGDPS inhibited cells. ATM phosphorylates PIDD1 at Thr788 which is crucial for 
caspase-2-PIDDosome formation, which promotes Mdm2 cleavage (Ando et al., 2012). Ku55933 
prevents cisplatin-induced Mdm2 cleavage (Terry et al., 2015). This ultimately suggests a role 
for cleaved caspase 2, Mdm2, and p53. More importantly, it is crucial to understand how 
GGDPS inhibition leads to changes in transcription. DGBP decreased Notch1 mRNA levels 
dose-dependently. How this happens is unclear, but one potential mechanism is through p53. 
Ral1B GTPase silencing activates and stabilizes p53 (Tecleab et al., 2014). P53 targets Notch1 
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transcription in skin fibroblasts (Lefort et al., 2007). Finally, Weissenrieder et al. found that 
DGBP decreases androgen receptor target gene transcription in prostate cancer cell lines 
(Weissenrieder et al., 2018). There is likely a role of geranylgeranylation in regulating 
transcription and in DNA-damage response. 
As both the Notch1 pathway and the Hippo pathway converge on c-abl (figure 29), one 
must ask if small GTPases interact with c-abl directly. It is possible for small GTPases to affect 
c-abl or BCR-ABL directly. BCR-ABL has a Rac binding site (Diekmann et al., 1991). Thus, it 
would be interesting to test c-abl inhibitors with a Rac GTPase inhibitor. This would be 
interesting because imatinib and farnesyl transferase inhibitors showed synergism when 
combined in both imatinib-resistant and imatinib-sensitive CML cell lines suggesting a role of 
farnesylated GTPases (Radujkovic et al., 2006). Overall, small GTPases may have a direct role 
on c-abl kinases and affect DNA damage-induced apoptosis through c-abl direct interaction.  
Conclusions 
Overall, we demonstrate that DGBP induces apoptosis through the DNA-damage 
response pathway in T-ALL cell lines. We show that GGPP can robustly rescue the pro-
apoptotic effect of zoledronate and DGBP. We also demonstrate that GGPP depletion increases 
levels of phosphorylated ERK. This we predict is related to DNA-damage response as well. The 
role of Notch1 as a driver for T-ALL is well established. We discovered that GGDPS inhibition 
decreased levels of Notch1. We also found that the anti-apoptotic effects of DGBP could be 
ameliorated by co-treatment with an ATM inhibitor and c-abl inhibitors. This result that indicates 
an isoprenoid biosynthesis pathway inhibitor can regulate apoptosis by the DNA-damage 






Figure 27. The isoprenoid biosynthesis pathway including FPP, GGPP and downstream 
effectors.  
HMG-CoA, 1, is used by HMG-CoA reductase (HMGCR) to biosynthesize mevalonate, 2. This 
step can be inhibited by statins. Mevalonate kinase (MVK), phosphomevalonate kinase (PMVK), 
and mevalonate diphosphodecarboxylase (MVD), convert mevalonate to isopentenyl 
diphosphate (IPP), 3. IPP is isomerized by isopentenyl-diphosphate delta isomerase (IDI) to form 
dimethylallyl diphosphate (DMAPP), 4. Farnesyl diphosphate synthase (FDPS) then uses 
DMAPP to biosynthesize farnesyl diphosphate (FPP), 5. This step can be inhibited by the 
nitrogenous bisphosphonates (N-BP). Geranylgeranyl diphosphate synthase then uses FPP and 
IPP to biosynthesize geranylgeranyl diphosphate (GGPP), 6. This step can be inhibited by 
geranylgeranyl diphosphate synthase inhibitors (GGSI).  FPP is also used by squalene synthase, 
which can be inhibited by squalene synthase inhibitors (SQI), to biosynthesize squalene, 7. 
Farnesyl transferase (FTase) uses FPP to farnesylate small GTPases such as KRas and laminA. 
This step can be inhibited by farnesyl transferase inhibitors (FTI). Dehydrodolichyl diphosphate 
synthase (DHDDS) uses FPP and IPP to biosynthesize dolichols, 8. This step can be inhibited by 
the cis prenyltransferase inhibitors (CPTI). GGPP is also used by geranylgeranyl transferase I 
(GGTase I) to geranylgeranylate proteins such as RhoA, Rap1A, and Ral1. This step can be 
inhibited by geranylgeranyl transferase I inhibitors (GGTI (I)). Geranylgeranyl transferase II also 
uses GGPP to geranylgeranylate other small GTPase proteins such as Rab3A and Rab5A. This 
can be inhibited by geranylgeranyl transferase II inhibitors (GGTI (II)). UBIAD1 uses GGPP to 





Figure 28. Novel thienopyrimide-based geranylgeranyl diphosphate synthase inhibitors 
(Lacbay et al., 2018).  





Figure 29. Thesis Summary.  
Adam10 cleaves full-length Notch1 which is then transported to the endosome to be cleaved by 
γ-secretase. GGDPS biosynthesizes GGPP which is then used by geranylgeranyl transferase II 
(GGTase II) to geranylgeranylate Rab GTPases. Rab GTPases can then localize to the endosome 
membrane and exert their function at the γ-secretase complex. This then allows for γ-secretase to 
cleave Notch and release NICD. NICD binds to ATM, preventing its activation. With GGDPS 
inhibition, however, GGPP is depleted preventing Rab from localizing to the endosome 
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membrane and preventing γ-secretase from cleaving Notch1. This also decreases transcription of 
Notch1. This then depletes NICD and allows for ATM activation leading to DNA damage 
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